Clarithromycin Dosage, Indications, Interactions, Side Effects, and More (2023)

Clarithromycin will increase the level or effect of acalabrutinib by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine. Avoid co-administration of acalabrutinib with strong CYP3A inhibitors. If a strong CYP3A inhibitor is required for a short period (eg, up to 7 days), temporarily withhold acalabrutinib.

Clarithromycin will increase the level or effect of adagrasib by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine. Avoid co-administration of adagrasib, a CYP3A4 substrate, with strong CYP3A4 inhibitors until adagrasib concentrations reach steady state (after ~8 days). If steady state is not reached, concomitant use of strong CYP3A4 inhibitors will increase adagrasib concentrations and the risk of toxicity.adagrasib, clarithromycin. Either one enhances the effects of the other on the QTc interval. Avoid or use alternative medicine. Each drug prolongs the QTc interval, which can increase the risk of Torsade de pointes, other serious arrhythmias, and sudden death. If co-administration is unavoidable, more frequent monitoring is recommended for these patients.

Clarithromycin increases ado-trastuzumab emtansine levels by affecting hepatic/intestinal CYP3A4 enzyme metabolism. Avoid or use alternative medicine. DM1, the cytotoxic component, is primarily metabolized by CYP3A4. Strong CYP3A4 inhibitors may increase exposure and toxicity to type 1 diabetes.

Clarithromycin increases afatinib levels via the P-glycoprotein efflux transporter (MDR1). Avoid or use alternative medicine. Reduce the daily dose of afatinib by 10 mg if not tolerated when co-administered with P-gp inhibitors.

Clarithromycin will increase the level or effect of almotriptan by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine.

Clarithromycin will increase the level or effect of alprazolam by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine.

Clarithromycin will increase the level or effect of amiodarone by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine. May cause QT prolongationAmiodarone and clarithromycin increase the QTc interval. Avoid or use alternative medicine.

Clarithromycin and amisulpride increase the QTc interval. Avoid or use alternative medicine. ECG monitoring is recommended if co-administered.

Clarithromycin will increase the level or effect of amitriptyline by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine.Amitriptyline and clarithromycin increase the QTc interval. Avoid or use alternative medicine.

Amoxapine and clarithromycin increase the QTc interval. Avoid or use alternative medicine.

Clarithromycin and anagrelide increase the QTc interval. Avoid or use alternative medicine.

Clarithromycin potentiates the effects of alpha antithrombin by slowing metabolism. Avoid or use alternative medicine.

Clarithromycin increases the effects of antithrombin III, decreasing its metabolism. Avoid or use alternative medicine.

Apalutamide will decrease the level or effect of clarithromycin by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine. Co-administration of apalutamide, a strong CYP3A4 inducer, with drugs that are CYP3A4 substrates may result in decreased exposure to these drugs. Avoid or substitute these medications for others when possible. Evaluate the loss of therapeutic effect if the medication is co-administered. Adjust the dose according to the prescribing information, if necessary.

Apomorphine and clarithromycin increase the QTc interval. Avoid or use alternative medicine.

Clarithromycin will increase the level or effect of aprepitant by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine.

Clarithromycin enhances the effects of argatroban by decreasing metabolism. Avoid or use alternative medicine.

Clarithromycin will increase the level or effect of aripiprazole by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine.Aripiprazole and clarithromycin increase the QTc interval. Avoid or use alternative medicine.

Arsenic trioxide and clarithromycin increase the QTc interval. Avoid or use alternative medicine.

Artemether and clarithromycin increase the QTc interval. Avoid or use alternative medicine.

Clarithromycin will increase the level or effect of artemether/lumefantrine by affecting the metabolism of the intestinal/hepatic enzyme CYP3A4. Avoid or use alternative medicine.Clarithromycin and artemether/lumefantrine increase the QTc interval. Avoid or use alternative medicine.

Clarithromycin and asenapine increase the QTc interval. Avoid or use alternative medicine.

Transdermal asenapine and clarithromycin increase the QTc interval. Avoid or use alternative medicine.

Atomoxetine and clarithromycin increase the QTc interval. Avoid or use alternative medicine.

Clarithromycin will increase the level or effect of atorvastatin by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine. Do not exceed an atorvastatin dose of 20 mg/day when co-administered with clarithromycin.Clarithromycin will increase the level or effect of atorvastatin via the P-glycoprotein efflux transporter (MDR1). Avoid or use alternative medicine. Do not exceed an atorvastatin dose of 20 mg/day when co-administered with clarithromycin.Clarithromycin increases the toxicity of atorvastatin by others (see comment). Avoid or use alternative medicine. Comment: OATP1B1 inhibitors may increase the risk of myopathy.

Clarithromycin will increase the level or effect of avanafil by affecting the metabolism of the intestinal/hepatic enzyme CYP3A4. Avoid or use alternative medicine. CYP3A4 inhibitors may decrease the elimination of avanafil by increasing the systemic exposure of avanafil. Significantly elevated levels can cause significant adverse effects, such as severe hypotension, syncope, visual changes, and priapism. Co-administration with potent CYP3A4 is contraindicated.

Clarithromycin will increase the level or effect of avapritinib by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine. Avoid co-administration of avapritinib with strong CYP3A4 inhibitors.

Clarithromycin increases axitinib levels by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine. If co-administration with strong CYP3A4 inhibitors cannot be avoided, reduce the axitinib dose by 50%.

Clarithromycin will increase the level or effect of bazedoxifene/conjugated estrogens by affecting the hepatic/intestinal metabolism of the CYP3A4 enzyme. Avoid or use alternative medicine.

Clarithromycin reduces the effects of live BCG vaccine through pharmacodynamic antagonism. Contraindicated. Wait until Abx Tx is complete before administering the live bacterial vaccine.

Clarithromycin will increase the level or effect of bedaquiline by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine. Avoid co-administration of bendacillin with strong CYP3A4 inhibitors for more than 14 consecutive days, unless the benefit of treatment outweighs the risk.

Clarithromycin potentiates the effects of bemiparin by decreasing its metabolism. Avoid or use alternative medicine.

Clarithromycin potentiates the effects of bivalirudin by decreasing metabolism. Avoid or use alternative medicine.

Clarithromycin increases bosutinib levels by affecting hepatic/intestinal metabolism of the CYP3A4 enzyme. Avoid or use alternative medicine. Strong CYP3A4 inhibitors increase bosutinib plasma concentration approximately 5-fold.Clarithromycin increases bosutinib levels via the P-glycoprotein efflux transporter (MDR1). Avoid or use alternative medicine.

Clarithromycin will increase the level or effect of brigatinib by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine. If concomitant use of a strong CYP3A inhibitor cannot be avoided, reduce the brigatinib once daily dose by approximately 50% (i.e., 180 mg to 90 mg or 90 mg to 60 mg). After discontinuing a strong CYP3A inhibitor, resume the dose of brigatinib that was tolerated prior to starting the strong CYP3A inhibitor.

Clarithromycin will increase the level or effect of bromocriptine by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine.

Clarithromycin will increase the level or effect of budesonide by affecting the hepatic/intestinal metabolism of the CYP3A4 enzyme. Avoid or use alternative medicine.

Clarithromycin will increase the level or effect of buprenorphine by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine.Clarithromycin and buprenorphine increase the QTc interval. Avoid or use alternative medicine.

Oral buprenorphine and clarithromycin increase the QTc interval. Avoid or use alternative medicine.

Subcutaneous implantation of buprenorphine and clarithromycin increase the QTc interval. Avoid or use alternative medicine.

Clarithromycin will increase the level or effect of transdermal buprenorphine by affecting hepatic/intestinal CYP3A4 enzyme metabolism. Avoid or use alternative medicine.Transdermal buprenorphine and clarithromycin increase the QTc interval. Avoid or use alternative medicine.

Buprenorphine, long-acting injection, and clarithromycin increase the QTc interval. Avoid or use alternative medicine.

Clarithromycin will increase the level or effect of buspirone by affecting the metabolism of the intestinal/hepatic enzyme CYP3A4. Avoid or use alternative medicine.

Clarithromycin will increase the level or effect of cabazitaxel by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine. Co-administration of cabazitaxel with strong CYP3A4 inhibitors should be avoided.

Clarithromycin increases cabergoline levels by decreasing metabolism. Contraindicated.

Clarithromycin will increase the level or effect of cabozantinib by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine. Avoid co-administration of cabozantinib with strong CYP3A4 inhibitors. If a strong CYP3A4 inhibitor is required, reduce the cabozantinib dose by 40 mg/day (Cometriq) or 20 mg/day (Cabometyx). Resume the previous dose 2-3 days after stopping the strong CYP3A4 inhibitor.

Clarithromycin will increase the level or effect of calcitriol by affecting the metabolism of the intestinal/hepatic enzyme CYP3A4. Avoid or use alternative medicine.

Clarithromycin will increase the level or effect of carbamazepine by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine. Monitor plasma levels when used concurrently

Clarithromycin increases ceritinib levels by affecting hepatic/intestinal metabolism of the CYP3A4 enzyme. Avoid or use alternative medicine. Avoid if possible. If concomitant use is unavoidable, reduce the ceritinib dose by approximately 33%. after stopping the strong CYP3A inhibitor, resume the previous dose.Ceritinib and clarithromycin increase the QTc interval. Avoid or use alternative medicine.

Clarithromycin will increase the level or effect of chloroquine by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine.

Chlorpromazine and clarithromycin increase the QTc interval. Avoid or use alternative medicine.

clarithromycin, cholera vaccine. pharmacodynamic competence. Avoid or use alternative medicine. Avoid concomitant administration of cholera vaccine with systemic antibiotics, as these agents may be active against the vaccine strain. Do not administer the cholera vaccine to patients who received oral or parenteral antibiotics within 14 days prior to vaccination.

Clarithromycin will increase the level or effect of cilostazol by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine.

Clarithromycin will increase the level or effect of cinacalcet by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine.

Clarithromycin and ciprofloxacin increase the QTc interval. Avoid or use alternative medicine.

clarithromycin, citalopram. Either increases the QTc toxicity of the other. Avoid or use alternative medicine. To monitor for QT/QTc prolongation and/or the development of ventricular tachyarrhythmias, the package insert recommends monitoring the QT interval or ECG.

Clarithromycin will increase the level or effect of clomipramine by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine.Clomipramine and clarithromycin increase the QTc interval. Avoid or use alternative medicine.

Clarithromycin will decrease the level or effect of clopidogrel by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine. CYP3A4 inhibition will decrease clopidogrel bioactivation

Clarithromycin will increase the level or effect of clozapine by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine.Clarithromycin and clozapine increase the QTc interval. Avoid or use alternative medicine.

cobicistat, clarithromycin. Either one increases the levels of the other, affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine. Consider alternative antibiotics with concomitant use of cobicistat co-administered with atazanavir or darunavir. .Clarithromycin will increase the level or effect of cobicistat by affecting hepatic/intestinal CYP3A4 enzyme metabolism. Avoid or use alternative medicine.

Clarithromycin will increase the level or effect of the Other's colchicine (see comment). Avoid or use alternative medicine. Colchicine is a substrate for P-gp and CYP3A4. Avoid use with drugs that are strong inhibitors of P-gp and CYP3A4. If co-administration is necessary, reduce the dose or frequency of colchicine as recommended in the prescribing information. The use of any colchicine product in combination with strong CYP3A4 inhibitors is contraindicated in patients with renal or hepatic impairment.

Clarithromycin will increase the level or effect of conjugated estrogens by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine.

Clarithromycin will increase the level or effect of vaginally conjugated estrogens by affecting the metabolism of the intestinal/hepatic enzyme CYP3A4. Avoid or use alternative medicine.

Clarithromycin will increase the level or effect of copanlisib by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine. If concomitant use with strong CYP3A inhibitors cannot be avoided, reduce the copanlisib dose to 45 mg.

Clarithromycin will increase the level or effect of cortisone by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine.

Clarithromycin and crizotinib increase the QTc interval. Avoid or use alternative medicine.

Clarithromycin will increase the level or effect of cyclosporine by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine.

Clarithromycin increases dabrafenib levels by affecting hepatic/intestinal metabolism of the CYP3A4 enzyme. Avoid or use alternative medicine.

Clarithromycin increases the effects of dalteparin by decreasing its metabolism. Avoid or use alternative medicine.

Clarithromycin will increase the level or effect of daridorexant by affecting hepatic/intestinal CYP3A4 enzyme metabolism. Avoid or use alternative medicine.

Clarithromycin will increase the level or effect of darifenacin by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine.

Clarithromycin will increase the level or effect of dasatinib by affecting the hepatic/intestinal metabolism of the CYP3A4 enzyme. Avoid or use alternative medicine.

Clarithromycin and degarelix increase the QTc interval. Avoid or use alternative medicine.

Desflurane and clarithromycin increase the QTc interval. Avoid or use alternative medicine.

desipramine and clarithromycin increase the QTc interval. Avoid or use alternative medicine.

Clarithromycin will increase the level or effect of dexamethasone by affecting hepatic/intestinal CYP3A4 enzyme metabolism. Avoid or use alternative medicine.

Clarithromycin will increase the level or effect of diazepam by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine.

Clarithromycin will increase the level or effect of digoxin by altering the intestinal flora. Applies only to the oral form of both agents. Avoid or use alternative medicine.

Clarithromycin and disopyramide increase the QTc interval. Avoid or use alternative medicine.

Clarithromycin and dofetilide increase the QTc interval. Avoid or use alternative medicine.

Donepezil and clarithromycin increase the QTc interval. Avoid or use alternative medicine.

Doxepin and clarithromycin increase the QTc interval. Avoid or use alternative medicine.

Clarithromycin will increase the level or effect of dronedarone by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine.Clarithromycin and dronedarone increase the QTc interval. Avoid or use alternative medicine.

Clarithromycin and droperidol increase the QTc interval. Avoid or use alternative medicine.

Clarithromycin will increase the level or effect of edoxaban via the P-glycoprotein efflux transporter (MDR1). Avoid or use alternative medicine. Dose adjustment may be necessary with strong P-gp inhibitors. Treatment of DVT/PE: Reduce dose to 30 mg PO once daily. NVAF: no dose reduction recommended

Efavirenz and clarithromycin increase the QTc interval. Avoid or use alternative medicine.

Clarithromycin will increase the level or effect of elastane by affecting the metabolism of the intestinal/hepatic enzyme CYP3A4. Avoid or use alternative medicine.

Clarithromycin will increase the level or effect of elbasvir/grazoprevir by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine.

Clarithromycin will increase the level or effect of eletriptan by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine.Clarithromycin increases eletriptan levels by decreasing metabolism. Contraindicated. Separate for 72 hours.

Clarithromycin and eleglustat increase the QTc interval. Avoid or use alternative medicine.

Clarithromycin increases eluxadoline levels by decreasing metabolism. Avoid or use alternative medicine. Reduce eluxadoline dose to 75 mg PO twice daily if co-administered with OATP1B1 inhibitors. .

Clarithromycin will increase the level or effect of elvitegravir/cobicistat/emtricitabine/tenofovir DF by affecting hepatic/intestinal CYP3A4 enzyme metabolism. Avoid or use alternative medicine.

Clarithromycin will increase the level or effect of encorafenib by affecting hepatic/intestinal CYP3A4 enzyme metabolism. Avoid or use alternative medicine. If concomitant use of a strong CYP3A4 inhibitor is unavoidable, reduce the encorafenib dose by one-third the dose (eg, reduce from 450 mg/day to 150 mg/day). After stopping the inhibitor for 3 to 5 elimination half-lives, resume the previous dose of encorafenib.Clarithromycin and encorafenib increase the QTc interval. Avoid or use alternative medicine.

Clarithromycin potentiates the effects of enoxaparin by decreasing metabolism. Avoid or use alternative medicine.

Clarithromycin and entrectinib increase the QTc interval. Avoid or use alternative medicine.Clarithromycin will increase the level or effect of entrectinib by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine. Avoid co-administration of strong CYP3A4 inhibitors with entrectinib, a CYP3A4 substrate. If co-administration is unavoidable, reduce the entrectinib dose to 100 mg/day in patients 12 years of age and older with a body surface area >1.50 m2. Continue the previous dose of entrectinib after discontinuing the strong CYP3A inhibitor for 3 to 5 elimination half-lives.

Clarithromycin will increase the level or effect of enzalutamide by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine.

Epinephrine and clarithromycin increase the QTc interval. Avoid or use alternative medicine.

Racemic epinephrine and clarithromycin increase the QTc interval. Avoid or use alternative medicine.

Clarithromycin will increase the level or effect of edafitinib by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine. If co-administration with strong CYP3A4 inhibitors cannot be avoided, monitor closely for adverse effects and consider reducing the dose accordingly. If the strong CYP3A4 inhibitor is discontinued, consider increasing the erdafitinib dose in the absence of drug-related toxicity.

Clarithromycin increases the levels of ergoloid mesylates by decreasing metabolism. Contraindicated.

Clarithromycin increases ergotamine levels by decreasing metabolism. Contraindicated.

Eribulin and clarithromycin increase the QTc interval. Avoid or use alternative medicine. Potential for increased QTc prolonging effects; if concomitant use is required, ECG monitoring is recommended.

Clarithromycin will increase the level or effect of erlotinib by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine.

Clarithromycin and erythromycin base increase the QTc interval. Avoid or use alternative medicine.

Clarithromycin will increase the level or effect of erythromycin ethylsuccinate by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine.Clarithromycin and erythromycin ethylsuccinate increase the QTc interval. Avoid or use alternative medicine.

Clarithromycin will increase the level or effect of erythromycin lactobionate by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine.Clarithromycin and erythromycin lactobion increase the QTc interval. Avoid or use alternative medicine.

Clarithromycin will increase the level or effect of erythromycin stearate by affecting hepatic/intestinal CYP3A4 enzyme metabolism. Avoid or use alternative medicine.Clarithromycin and erythromycin stearate increase the QTc interval. Avoid or use alternative medicine.

clarithromycin, escitalopram. Either increases the QTc toxicity of the other. Avoid or use alternative medicine. To monitor for QT/QTc prolongation and/or the development of ventricular tachyarrhythmias, the package insert recommends monitoring the QT interval or ECG.Escitalopram increases the toxicity of clarithromycin during the QTc interval. Avoid or use alternative medicine.Clarithromycin will increase the level or effect of escitalopram by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine.

Clarithromycin will increase the level or effect of estradiol by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine.

Clarithromycin will increase the level or effect of synthetic conjugated estrogens by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine.

Clarithromycin will increase the level or effect of etropipate by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine.

Clarithromycin will increase the level or effect of etonogestrel by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine.

Clarithromycin will increase the level or effect of etravirine by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine.

Clarithromycin will increase the level or effect of everolimus by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine.Clarithromycin will increase the level or effect of everolimus via the P-glycoprotein efflux transporter (MDR1). Contraindicated.

Clarithromycin will increase the level or effect of fedratinib by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine. If co-administration of fedratinib with strong CYP3A4 inhibitors cannot be avoided, reduce fedratinib dose to 200 mg/day. If the CYP3A4 inhibitor is discontinued, increase the fedratinib dose to 300 mg/day for 2 weeks and then to 400 mg/day as tolerated.

Clarithromycin will increase the level or effect of felbamate by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine.

Clarithromycin will increase the level or effect of fentanyl by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine. If co-administration of CYP3A4 inhibitors with fentanyl is required, monitor patients for respiratory depression and sedation at frequent intervals and consider fentanyl dose adjustment until stable drug effects are achieved.

Clarithromycin will increase the level or effect of intranasal fentanyl by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine. If co-administration of CYP3A4 inhibitors with fentanyl is required, monitor patients for respiratory depression and sedation at frequent intervals and consider fentanyl dose adjustment until stable drug effects are achieved.

Clarithromycin will increase the level or effect of transdermal fentanyl by affecting the hepatic/intestinal metabolism of the CYP3A4 enzyme. Avoid or use alternative medicine. If co-administration of CYP3A4 inhibitors with fentanyl is required, monitor patients for respiratory depression and sedation at frequent intervals and consider fentanyl dose adjustment until stable drug effects are achieved.

Clarithromycin will increase the level or effect of transmucosal fentanyl by affecting hepatic/intestinal CYP3A4 enzyme metabolism. Avoid or use alternative medicine. If co-administration of CYP3A4 inhibitors with fentanyl is required, monitor patients for respiratory depression and sedation at frequent intervals and consider fentanyl dose adjustment until stable drug effects are achieved.

Clarithromycin will increase the level or effect of fesoterodine by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine.

Clarithromycin will decrease the level or effect of fexinidazole by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine. If co-administration cannot be avoided, monitor fexinidazole for reduced efficacy due to reduced plasma concentrations of the active metabolites M1 and M2.Fexinidazole and clarithromycin increase the QTc interval. Avoid or use alternative medicine. Avoid concomitant administration of fexinidazole with medicinal products known to block potassium channels or prolong the QT interval.Fexinidazole will increase the level or effect of clarithromycin by affecting the metabolism of the intestinal/hepatic enzyme CYP3A4. Avoid or use alternative medicine. Fexinidazole inhibits CYP3A4. Co-administration may increase the risk of adverse effects from CYP3A4 substrates.

Fingolimod and clarithromycin increase the QTc interval. Avoid or use alternative medicine.

Clarithromycin and fluconazole increase the QTc interval. Avoid or use alternative medicine.

Clarithromycin will increase the level or effect of fludrocortisone by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine.

Fluphenazine and clarithromycin increase the QTc interval. Avoid or use alternative medicine.

Clarithromycin will increase the level or effect of intranasal fluticasone by affecting hepatic/intestinal CYP3A4 enzyme metabolism. Avoid or use alternative medicine. Strong CYP3A4 inhibitors may increase the systemic side effects of corticosteroids. monitor for signs/symptoms of high corticosteroid concentrations, including Cushing-like signs/symptoms.

Clarithromycin increases the toxicity of fluvastatin by others (see comment). Avoid or use alternative medicine. Comment: OATP1B1 inhibitors may increase the risk of myopathy.

Clarithromycin potentiates the effects of fondaparinux by decreasing its metabolism. Avoid or use alternative medicine.

Clarithromycin and formoterol increase the QTc interval. Avoid or use alternative medicine.

Clarithromycin will increase the level or effect of fosamprenavir by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine.

Clarithromycin will increase the level or effect of fosaprepitant by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine.

Clarithromycin and fostemsavir increase the QTc interval. Avoid or use alternative medicine.

Clarithromycin will increase the level or effect of futitinib by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine. Co-administration of fupitinib with drugs that are dual inhibitors of P-gp and CYP3A may increase the incidence/severity of fupitinib toxicity.

Clarithromycin and gadovenate increase the QTc interval. Contraindicated.

Clarithromycin and gemifloxacin increase the QTc interval. Avoid or use alternative medicine.

Clarithromycin will increase the level or effect of gilteritinib by affecting hepatic/intestinal CYP3A4 enzyme metabolism. Avoid or use alternative medicine. Consider alternatives to any strong CYP3A4 inhibitor when co-administered with gilteritinib. If such a combination cannot be avoided, monitor closely for gilteritinib-related adverse events. Withdrawal and dose reduction of gilteritinib in patients with severe or life-threatening toxicity.Gilteritinib and clarithromycin increase the QTc interval. Avoid or use alternative medicine. If co-administration is necessary, monitor ECG.

Clarithromycin will increase the level or effect of glasdegib by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine. Consider alternative therapies other than strong CYP3A inhibitors or manage risk of adverse effects, including QTc interval prolongation.Clarithromycin and gladegib increase the QTc interval. Avoid or use alternative medicine. If co-administration is unavoidable, monitor for increased risk of QTc prolongation.

Clarithromycin and granisetron increase the QTc interval. Avoid or use alternative medicine.

Clarithromycin and haloperidol increase the QTc interval. Avoid or use alternative medicine.Clarithromycin will increase the level or effect of haloperidol by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine.

Clarithromycin enhances the effects of heparin by reducing metabolism. Avoid or use alternative medicine.

Clarithromycin will increase the level or effect of hydrocortisone by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine.

Hydroxychloroquine sulfate and clarithromycin increase the QTc interval. Avoid or use alternative medicine.

Clarithromycin will increase the level or effect of hydroxyprogesterone caproate (DSC) by affecting hepatic/intestinal CYP3A4 enzyme metabolism. Avoid or use alternative medicine.

Clarithromycin increases ibrutinib levels by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine. Avoid concomitant use of ibrutinib and strong CYP3A4 inhibitors. If a strong CYP3A4 inhibitor is required in the short term (eg, anti-infective for = 7 days), withhold ibrutinib until the strong CYP3A4 inhibitor is withdrawn.

Clarithromycin will increase the level or effect of idelalisib by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine. If co-administered with strong CYP3A inhibitors, monitor for signs of idelalisib toxicity. follow recommendations for dose modifications if adverse effects occurIdelalisib will increase the level or effect of clarithromycin by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine. Idelalisib is a potent CYP3A inhibitor. Avoid co-administration with sensitive CYP3A substrates.

Clarithromycin will increase the level or effect of imipramine by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine.Imipramine and clarithromycin increase the QTc interval. Avoid or use alternative medicine.

Clarithromycin will increase the level or effect of indinavir by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine.

Clarithromycin will increase the level or effect of infigratinib by affecting hepatic/intestinal CYP3A4 enzyme metabolism. Avoid or use alternative medicine.

Inotuzumab and clarithromycin increase the QTc interval. Avoid or use alternative medicine. If concomitant use cannot be avoided, obtain electrocardiogram and electrolytes before and after initiation of any drug known to prolong the QTc interval and monitor periodically as clinically indicated during treatment.

Clarithromycin will increase the level or effect of irinotecan through the P-glycoprotein efflux transporter (MDR1). Avoid or use alternative medicine.Clarithromycin will increase the level or effect of irinotecan by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine.

Clarithromycin will increase the level or effect of liposomal irinotecan via the P-glycoprotein efflux transporter (MDR1). Avoid or use alternative medicine.Clarithromycin will increase the level or effect of liposomal irinotecan by affecting hepatic/intestinal CYP3A4 enzyme metabolism. Avoid or use alternative medicine. UGT1A1 inhibitors reduce the metabolism of irinotecan

Clarithromycin and isoflurane increase the QTc interval. Avoid or use alternative medicine.

Clarithromycin and isradipine increase the QTc interval. Avoid or use alternative medicine.

Itraconazole will increase the level or effect of clarithromycin by affecting the metabolism of the intestinal/hepatic enzyme CYP3A4. Avoid or use alternative medicine.

Clarithromycin will increase the level or effect of ivosidenib by affecting hepatic/intestinal CYP3A4 enzyme metabolism. Avoid or use alternative medicine. Avoid co-administration of strong CYP3A4 inhibitors with ivosidenib or alternative surrogate therapies. If co-administration of a strong CYP3A4 inhibitor is unavoidable, reduce the ivosidenib dose to 250 mg daily. If the strong inhibitor is discontinued, increase the ivosidenib dose (after at least 5 half-lives of the strong CYP3A4 inhibitor) to the recommended dose of 500 mg daily. Watch for increased risk of QTc prolongation.Ivosidenib and clarithromycin increase the QTc interval. Avoid or use alternative medicine. Avoid co-administration of drugs that prolong the QTc interval with ivosidenib or alternative replacement therapies. If concomitant administration of a drug that prolongs the QTc interval is unavoidable, monitor for increased risk of QTc prolongation.Ivosidenib will decrease the level or effect of clarithromycin by affecting the metabolism of the intestinal/hepatic enzyme CYP3A4. Avoid or use alternative medicine. Avoid co-administration of sensitive CYP3A4 substrates with ivosidenib or alternative surrogate therapies. If co-administration is unavoidable, monitor patients for loss of therapeutic effect of these drugs.

Clarithromycin will increase the level or effect of ixampelone by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine.

Clarithromycin will increase the level or effect of ketamine by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine.

Clarithromycin and ketoconazole increase the QTc interval. Avoid or use alternative medicine.Ketoconazole will increase the level or effect of clarithromycin by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine.

Clarithromycin will increase the level or effect of lapatinib by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine.

Clarithromycin will increase the level or effect of larotrectinib by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine.

Clarithromycin will increase the level or effect of lefamulin by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine. Avoid co-administration of lefamulin with strong CYP3A inhibitors.Clarithromycin and lefamulin increase the QTc interval. Avoid or use alternative medicine.

Clarithromycin will increase the level or effect of levorexant by affecting the hepatic/intestinal metabolism of the CYP3A4 enzyme. Avoid or use alternative medicine. Avoid co-administration of leborexant with moderate or strong CYP3A inhibitors.

Clarithromycin will increase the level or effect of leniolisib by affecting hepatic/intestinal CYP3A4 enzyme metabolism. Avoid or use alternative medicine.

Levoketoconazole will increase the level or effect of clarithromycin by affecting hepatic/intestinal CYP3A4 enzyme metabolism. Avoid or use alternative medicine.Clarithromycin and lecenoconazole increase the QTc interval. Avoid or use alternative medicine.

Clarithromycin and lithium increase the QTc interval. Avoid or use alternative medicine.

Lofepramine and clarithromycin increase the QTc interval. Avoid or use alternative medicine.

Clarithromycin and lofexidine increase the QTc interval. Avoid or use alternative medicine.

Clarithromycin and loperamide increase the QTc interval. Avoid or use alternative medicine.

Clarithromycin will increase the level or effect of lopinavir by affecting the metabolism of the intestinal/hepatic enzyme CYP3A4. Avoid or use alternative medicine.Lopinavir will increase the level or effect of clarithromycin by affecting the metabolism of the intestinal/hepatic enzyme CYP3A4. Avoid or use alternative medicine.Clarithromycin and lopinavir increase the QTc interval. Avoid or use alternative medicine.

Clarithromycin will increase the level or effect of loratadine by affecting the metabolism of the intestinal/hepatic enzyme CYP3A4. Avoid or use alternative medicine.

Clarithromycin will increase the level or effect of lorlatinib by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine. Avoid co-administration of lorlatinib with strong CYP3A inhibitors. If unavoidable, reduce the lorlatinib dose by 25 mg/day. If the strong CYP3A inhibitor is withdrawn, it should be preboosted with lorlatinib (dose after 3 plasma half-lives of the strong CYP3A inhibitor). Consult the monograph for more details.Lorlatinib will decrease the level or effect of clarithromycin by affecting hepatic/intestinal CYP3A4 enzyme metabolism. Avoid or use alternative medicine.

Lumacaftor/ivacaftor will decrease the level or effect of clarithromycin by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine.

Clarithromycin will increase the level or effect of lumefantrine by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine.Clarithromycin and lumefantrine increase the QTc interval. Avoid or use alternative medicine.

Clarithromycin will increase the level or effect of lurbinectidin by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine. If co-administration is unavoidable, reduce the lurbinectidin dose by 50%. After discontinuing the strong CYP3A inhibitor for 5 half-lives, increase lurbinectidine to the dose used prior to co-administration.

Macimorelin and clarithromycin increase the QTc interval. Avoid or use alternative medicine. Macimorelin causes an ~11 ms increase in the corrected QT interval. Avoid co-administration with drugs that prolong the QT interval, which may increase the risk of torsades de pointes. Allow adequate washout time for drugs known to prolong the QT interval before administering macimorelin.

Clarithromycin will increase the level or effect of macitentan by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine. Avoid co-administration of macitentan with strong CYP3A4 inhibitors.

Maprotiline and clarithromycin increase the QTc interval. Avoid or use alternative medicine.

Clarithromycin will increase the level or effect of mefloquine by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine. Potential for increased toxicity. Avoid co-administration during and for 15 weeks after discontinuation of mefloquine.Clarithromycin and mefloquine increase the QTc interval. Avoid or use alternative medicine.

Clarithromycin will increase the level or effect of mestranol by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine.

Clarithromycin will increase the level or effect of methadone by affecting the metabolism of the intestinal/hepatic enzyme CYP3A4. Avoid or use alternative medicine.

Clarithromycin increases methylergonovine levels by decreasing metabolism. Contraindicated.

Clarithromycin will increase the level or effect of methylprednisolone by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine.

Clarithromycin will increase the level or effect of midazolam by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine.

Clarithromycin will increase the level or effect of intranasal midazolam by affecting hepatic/intestinal CYP3A4 enzyme metabolism. Avoid or use alternative medicine. Co-administration of strong CYP3A4 inhibitors with intranasal midazolam results in increased systemic exposure to midazolam, which may prolong sedation.

Clarithromycin will increase the level or effect of midostaurin by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine. If co-administration with strong CYP3A4 inhibitors cannot be avoided, monitor midostaurin for increased risk of adverse effects, especially during the first week of treatment.Clarithromycin and midostaurin increase the QTc interval. Avoid or use alternative medicine.

Mifepristone will increase the level or effect of clarithromycin by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine.Clarithromycin and mifepristone increase the QTc interval. Avoid or use alternative medicine.

Clarithromycin will increase the level or effect of mirtazapine by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine.Clarithromycin and mirtazapine increase the QTc interval. Avoid or use alternative medicine.

Clarithromycin will increase the level or effect of mobocertinib by affecting hepatic/intestinal CYP3A4 enzyme metabolism. Avoid or use alternative medicine.Mobocertinib and clarithromycin increase the QTc interval. Avoid or use alternative medicine. If co-administration is unavoidable, reduce the mobocertinib dose and monitor the QTc interval more frequently.

Clarithromycin will increase the level or effect of modafinil by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine.

Clarithromycin and moxifloxacin increase the QTc interval. Avoid or use alternative medicine.

Nefazodone will increase the level or effect of clarithromycin by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine.Clarithromycin will increase the level or effect of nefazodone by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine.

Clarithromycin will increase the level or effect of nelfinavir by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine.

Clarithromycin will increase the level or effect of neratinib by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine. Avoid co-administration of neratinib with strong/moderate CYP3A4 inhibitors.

Clarithromycin will increase the level or effect of nevirapine by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine.

Clarithromycin will increase the level or effect of nilotinib by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine.Clarithromycin and nilotinib increase the QTc interval. Avoid or use alternative medicine.

Nortriptyline and clarithromycin increase the QTc interval. Avoid or use alternative medicine.

Clarithromycin and octreotide increase the QTc interval. Avoid or use alternative medicine.

Clarithromycin and octreotide (antidote) increase the QTc interval. Avoid or use alternative medicine.

Clarithromycin and olanzapine increase the QTc interval. Avoid or use alternative medicine. Limited data, including a few case reports, suggest that olanzapine may be associated with significant QTc prolongation in rare cases.

Clarithromycin will increase the level or effect of olaparib by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine. If co-administration with strong CYP3A inhibitors cannot be avoided, reduce the olaparib dose to 150 mg (capsule) or 100 mg (tablet) orally twice daily. Do not substitute pills for capsules.

Clarithromycin will increase the level or effect of omaveloxolone by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine. If unavoidable, reduce the omaveloxolone dose to 50 mg/day. Monitor closely and discontinue if adverse effects occur.

Clarithromycin will increase the level or effect of ombitasvir/paritaprevir/ritonavir by affecting the hepatic/intestinal metabolism of the CYP3A4 enzyme. Avoid or use alternative medicine.

Clarithromycin will increase the level or effect of ombitasvir/paritaprevir/ritonavir and dasabuvir (DSC) by affecting hepatic/intestinal CYP3A4 enzyme metabolism. Avoid or use alternative medicine.

Clarithromycin and ondansetron increase the QTc interval. Avoid or use alternative medicine. Avoid in case of congenital long QT syndrome. ECG monitoring with concomitant medications that prolong the QT interval, electrolyte abnormalities, congestive heart failure, or bradyarrhythmias is recommended. Potential for increased ondansetron levels.Clarithromycin will increase the level or effect of ondansetron by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine.

Clarithromycin will increase the level or effect of osimertinib by affecting hepatic/intestinal CYP3A4 enzyme metabolism. Avoid or use alternative medicine. Avoid co-administration of osimertinib with strong CYP3A4 inhibitors. If there is no alternative treatment, monitor the patient more closely for adverse effects.

Clarithromycin and oxaliplatin increase the QTc interval. Avoid or use alternative medicine.

Clarithromycin increases oxycodone levels by affecting the metabolism of the intestinal/hepatic enzyme CYP3A4. Avoid or use alternative medicine. A dose reduction of oxycodone may be necessary when co-administered with strong CYP3A4 inhibitors.

Clarithromycin will increase the level or effect of palbociclib by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine. Avoid co-administration of palbociclib with strong CYP3A inhibitors. If this cannot be avoided, reduce the palbociclib dose to 75 mg/day.

Clarithromycin will increase the level or effect of palovarotene by affecting hepatic/intestinal CYP3A4 enzyme metabolism. Avoid or use alternative medicine.

Clarithromycin and panobinostat increase the QTc interval. Avoid or use alternative medicine. Panobinostat is known to significantly prolong the QT interval. The prescribing information for Panovinostat states that its use with drugs known to prolong the QTc interval is not recommended.

Clarithromycin will increase the level or effect of pazopanib by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine. If possible, avoid co-administration of pazopanib with strong CYP3A4 inhibitors. if co-administered, reduce pazopanib dose to 400 mg/day

Clarithromycin will increase the level or effect of pemigatinib by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine. If co-administration with strong or moderate CYP3A4 inhibitors is unavoidable, reduce the pemigatinib dose (see drug monograph for dose modifications). After stopping the CYP3A4 inhibitor for 3 elimination half-lives, the previous dose of pemigatinib can be restarted.

Perphenazine and clarithromycin increase the QTc interval. Avoid or use alternative medicine.

Clarithromycin will increase the level or effect of pexidartinib by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine. If co-administration with strong or moderate CYP3A4 inhibitors is unavoidable, reduce the pexidartinib dose (see drug monograph for dose modifications). After stopping the CYP3A4 inhibitor for 3 elimination half-lives, the previous dose of pexidartinib can be restarted.

Clarithromycin potentiates the effects of phenidon by decreasing metabolism. Avoid or use alternative medicine.

Clarithromycin will increase the level or effect of pimavanserin by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine. Reduce dose to 17 mg/day if pimavanserin is co-administered with strong CYP3A4 inhibitors.Clarithromycin and pimavanserin increase the QTc interval. Avoid or use alternative medicine.

Clarithromycin will increase the level or effect of pirtobrutinib by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine. If co-administration is unavoidable, reduce pirtobrutinib by 50 mg. If the current dose of pirtobrutinib is 50 mg per day, stop pirtobrutinib while using a strong CYP3A inhibitor. Once the strong CYP3A inhibitor has been withdrawn for 5 half-lives, restart pirtobrutinib at the dose taken prior to starting the strong CYP3A inhibitor.

Clarithromycin and Pitolist increase the QTc interval. Avoid or use alternative medicine.Clarithromycin will increase the level or effect of the petiole by affecting the metabolism of the hepatic/intestinal CYP3A4 enzyme. Avoid or use alternative medicine.

Clarithromycin increases pomalidomide levels by affecting hepatic/intestinal metabolism of the CYP3A4 enzyme. Avoid or use alternative medicine.Clarithromycin increases pomalidomide levels via the P-glycoprotein efflux transporter (MDR1). Avoid or use alternative medicine.

Clarithromycin increases ponatinib levels by affecting hepatic/intestinal metabolism of the CYP3A4 enzyme. Avoid or use alternative medicine. Reduce the starting dose of ponatinib to 30 mg daily if co-administration with strong CYP3A4 inhibitors cannot be avoided.

Clarithromycin and ponesimod increase the QTc interval. Avoid or use alternative medicine.

Clarithromycin will increase the level or effect of pralcetinib by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine.

Clarithromycin will increase the level or effect of prednisone by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine.

Clarithromycin will increase the level or effect of primaquine by affecting the metabolism of the intestinal/hepatic enzyme CYP3A4. Avoid or use alternative medicine.Clarithromycin and primaquine increase the QTc interval. Avoid or use alternative medicine.

Clarithromycin and procainamide increase the QTc interval. Avoid or use alternative medicine.

Prochlorperazine and clarithromycin increase the QTc interval. Avoid or use alternative medicine.

Clarithromycin will increase the level or effect of intravaginal progesterone gel by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine.

Clarithromycin will increase the level or effect of micronized progesterone by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine.

Clarithromycin will increase the level or effect of progesterone by naturally affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine.

Promazine and clarithromycin increase the QTc interval. Avoid or use alternative medicine.

Promethazine and clarithromycin increase the QTc interval. Avoid or use alternative medicine.

Clarithromycin and propafenone increase the QTc interval. Avoid or use alternative medicine.

Clarithromycin potentiates the effects of protamine by decreasing metabolism. Avoid or use alternative medicine.

Protriptyline and clarithromycin increase the QTc interval. Avoid or use alternative medicine.

Clarithromycin will increase the level or effect of quetiapine by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine.

Clarithromycin will increase the level or effect of quinidine by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine.

Quinupristin/dalfopristin increases clarithromycin levels by reducing metabolism. Contraindicated. Risk of prolonged QTc interval.

Clarithromycin will increase the level or effect of ranolazine by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine.

Clarithromycin will increase the level or effect of repaglinide by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine.

Clarithromycin will increase the level or effect of ribociclib by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine. If it is necessary to co-administer a strong CYP3A inhibitor with ribociclib, reduce the starting dose of ribociclib to 400 mg/day.Ribosilib and clarithromycin increase the QTc interval. Avoid or use alternative medicine.Ribociclib will increase the level or effect of clarithromycin by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine.

Clarithromycin will increase the level or effect of rifabutin by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine.

Clarithromycin will increase the level or effect of rimegepant by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine.Clarithromycin will increase the level or effect of rimegepant via the P-glycoprotein efflux transporter (MDR1). Avoid or use alternative medicine.

Clarithromycin will increase the level or effect of ritonavir by affecting the metabolism of the intestinal/hepatic enzyme CYP3A4. Avoid or use alternative medicine.

Clarithromycin increases rivaroxaban levels by affecting hepatic/intestinal metabolism of the CYP3A4 enzyme. Avoid or use alternative medicine. Avoid concomitant use of rivaroxaban and a combination of Pgp and strong CYP3A4 inhibitors. The combination can cause significant increases in rivaroxaban levels and increase the risk of bleeding. However, according to the manufacturer, although clarithromycin is a combined inhibitor of P-gp and CYP3A4, pharmacokinetic data suggest that caution is not required when co-administering rivaroxaban in patients with normal renal function, as a change is unlikely to occur. at the exhibition. Does it affect the risk of bleeding? However, the combination should be avoided in patients with mild or moderate renal impairment (CrCl 15-80 ml/min).

Clarithromycin will increase the level or effect of romidepsin by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine. If possible, co-administration with strong 3A4 inhibitors should be avoided.

Clarithromycin increases the toxicity of rosuvastatin by others (see comment). Avoid or use alternative medicine. Comment: OATP1B1 inhibitors may increase the risk of myopathy.

Clarithromycin will increase the level or effect of ruxolitinib by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine. Reduce the starting dose of ruxolitinib to 10 mg daily with a platelet count of 100 x 10^9/L or greater and concomitant strong CYP3A4 inhibitors. avoid with platelet count <100 X 10^9/L

Clarithromycin will increase the level or effect of topical ruxolitinib by affecting hepatic/intestinal CYP3A4 enzyme metabolism. Avoid or use alternative medicine. Reduce the starting dose of ruxolitinib to 10 mg daily with a platelet count of 100 x 10^9/L or greater and concomitant strong CYP3A4 inhibitors. avoid with platelet count <100 X 10^9/L

Clarithromycin will increase the level or effect of saquinavir by affecting the metabolism of the intestinal/hepatic enzyme CYP3A4. Avoid or use alternative medicine.Saquinavir will increase the level or effect of clarithromycin by affecting the metabolism of the intestinal/hepatic enzyme CYP3A4. Contraindicated.

Clarithromycin will increase the level or effect of selpercatinib by affecting hepatic/intestinal CYP3A4 enzyme metabolism. Avoid or use alternative medicine.

Clarithromycin will increase the level or effect of selumetinib by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine. If co-administration with strong or moderate CYP3A4 inhibitors cannot be avoided, reduce the selumetinib dose (see selumetinib monograph for more information). After stopping the strong or moderate CYP3A4 inhibitor for 3 elimination half-lives, resume the selumetinib dose taken before starting the inhibitor.

Clarithromycin and sertraline increase the QTc interval. Avoid or use alternative medicine.

Clarithromycin and sevoflurane increase the QTc interval. Avoid or use alternative medicine.

Clarithromycin will increase the level or effect of sildenafil by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine. Co-administration of these phosphodiesterase inhibitors with clarithromycin, a CYP3A4 inhibitor, is not recommended. Increased systemic exposure to these drugs may occur with clarithromycin. consider reducing the dose of phosphodiesterase inhibitors.

Clarithromycin will increase the level or effect of silodosin by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine.

Clarithromycin will increase the level or effect of siponimod by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine. Co-administration of siponimod with a moderate or strong CYP3A4 inhibitor PLUS a moderate or strong CYP2C9 inhibitor is not recommended.Clarithromycin and siponimod increase the QTc interval. Avoid or use alternative medicine.

Clarithromycin will increase the level or effect of sirolimus by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine.

Clarithromycin will increase the level or effect of solifenacin by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine.Clarithromycin and solifenacin increase the QTc interval. Avoid or use alternative medicine.

Clarithromycin will increase the level or effect of sonidegib by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine. Avoid co-administration of sonidegib with strong CYP3A4 inhibitors.

Clarithromycin will increase the level or effect of sorafenib by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine.

Clarithromycin and sotalol increase the QTc interval. Avoid or use alternative medicine.

Clarithromycin will increase the level or effect of sparsentan by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine. If unavoidable, discontinue sparsentan treatment. When restarting sparsesentan, consider adjusting the dose.

Clarithromycin will increase the level or effect of stiripentol by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine.

Clarithromycin will increase the level or effect of sulbactam/durlobactam by others (see comment). Avoid or use alternative medicine. OATP1 is expected to actively secrete sulbactam as an important part of total clearance. Therefore, OAT1 inhibition may increase sulbactam plasma concentrations.

Clarithromycin will increase the level or effect of sunitinib by affecting the hepatic/intestinal metabolism of the CYP3A4 enzyme. Avoid or use alternative medicine.Clarithromycin and sunitinib increase the QTc interval. Avoid or use alternative medicine.

Clarithromycin increases suvorexant levels by affecting hepatic/intestinal metabolism of the CYP3A4 enzyme. Avoid or use alternative medicine. Suvorexant is not recommended with the use of strong CYP3A4 inhibitors.

Clarithromycin will increase the level or effect of tacrolimus by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine.Clarithromycin and tacrolimus increase the QTc interval. Avoid or use alternative medicine.

Clarithromycin will increase the level or effect of tadalafil by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine. For DM, limit tadalafil to a maximum of 2.5 mg/day (for daily use) or a 10 mg dose every 72 hours (for use as needed). Avoid concomitant use of tadalafil for pulmonary hypertension in patients receiving strong CYP3A4 inhibitors.

Clarithromycin will increase the level or effect of talazoparib via the P-glycoprotein efflux transporter (MDR1). Avoid or use alternative medicine. If co-administration with certain P-gp inhibitors (eg, amiodarone, carvedilol, clarithromycin, itraconazole, verapamil) cannot be avoided, reduce the talazoparib dose to 0.75 mg daily. Once P-gp inhibitors are discontinued, increase the talazoparib dose (after 3 to 5 inhibitor half-lives) to the dose used prior to initiation of P-gp inhibitors.

Clarithromycin increases tamsulosin levels by affecting the metabolism of the intestinal/hepatic enzyme CYP3A4. Avoid or use alternative medicine.

Clarithromycin will increase the level or effect of tazemetostat by affecting hepatic/intestinal CYP3A4 enzyme metabolism. Avoid or use alternative medicine. Avoid co-administration of tazemetostat with strong CYP3A4 inhibitors.

Clarithromycin will increase the level or effect of temsirolimus by affecting hepatic/intestinal CYP3A4 enzyme metabolism. Avoid or use alternative medicine.

Clarithromycin will increase the level or effect of teniposide by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine.

Clarithromycin and tetrabenazine increase the QTc interval. Avoid or use alternative medicine.

Clarithromycin will increase the level or effect of theophylline by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine.

Thioridazine and clarithromycin increase the QTc interval. Avoid or use alternative medicine.

Clarithromycin will increase the level or effect of tiagabine by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine.

Clarithromycin will increase the level or effect of tipranavir by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine.tipranavir, clarithromycin. Either increases the levels of the other, slowing the metabolism. Avoid or use alternative medicine. Dose adjustments are not required for normal renal function. If CrCl = 30 60 ml/min, reduce the clarithromycin dose by 50%. If CrCl < 30 mL/min, reduce the clarithromycin dose by 75%.Tipranavir will increase the level or effect of clarithromycin by affecting the metabolism of the intestinal/hepatic enzyme CYP3A4. Avoid or use alternative medicine.

Clarithromycin increases tofacitinib levels by affecting the metabolism of the intestinal/hepatic enzyme CYP3A4. Avoid or use alternative medicine. Reduce tofacitinib dose to 5 mg daily when co-administered with strong CYP3A4 inhibitors.

Clarithromycin will increase the level or effect of tolterodine by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine.

Clarithromycin will increase the level or effect of tolvaptan by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine.

Clarithromycin will increase the level or effect of topotecan via the P-glycoprotein efflux transporter (MDR1). Avoid or use alternative medicine. The package insert for topotecan PO recommends avoiding the concomitant use of P-gp inhibitors. Interaction with intravenous topotecan may be less severe but still potentially clinically relevant.

Clarithromycin increases toremifene levels by decreasing metabolism. Avoid or use alternative medicine. Concomitant use of toremifene with agents that prolong the QT interval should be avoided. If concomitant use is necessary, it is recommended to discontinue toremifene. If discontinuation of treatment is not possible, patients requiring treatment with a drug that prolongs the QT interval should be closely monitored. ECG should be obtained in high-risk patients.Clarithromycin will increase the level or effect of toremifene by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine.Clarithromycin and toremifene increase the QTc interval. Avoid or use alternative medicine.

Clarithromycin will increase the level or effect of trabectedin by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine. If a strong CYP3A inhibitor is required in the short term (eg, less than 14 days), give a strong CYP3A inhibitor 1 week after the trabectedin infusion and discontinue the day before the next trabectedin infusion.

Clarithromycin will increase the level or effect of trazodone by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine.Trazodone and clarithromycin increase the QTc interval. Avoid or use alternative medicine.

Clarithromycin will increase the level or effect of triamcinolone acetonide injection suspension by affecting hepatic/intestinal CYP3A4 enzyme metabolism. Avoid or use alternative medicine.

Clarithromycin will increase the level or effect of triazolam by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine.

Clarithromycin and triclavendazole increase the QTc interval. Avoid or use alternative medicine.

Trifluoperazine and clarithromycin increase the QTc interval. Avoid or use alternative medicine.

Trimipramine and clarithromycin increase the QTc interval. Avoid or use alternative medicine.

Tucatinib will increase the level or effect of clarithromycin by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine. Avoid concomitant use of tucatinib with CYP3A substrates, where small changes in concentration may cause serious or life-threatening toxicities. If unavoidable, reduce the CYP3A substrate dose according to the product label.

Clarithromycin reduces the effects of live typhoid vaccine through pharmacodynamic antagonism. Contraindicated. Wait until Abx Tx is complete before administering the live bacterial vaccine.

Clarithromycin will increase the level or effect of ubrogepant by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Contraindicated.

Clarithromycin increases the toxicity of inhaled umeclidinium bromide/vilanterol during the QTc interval. Avoid or use alternative medicine. Use extreme caution when co-administering vilanterol with medicinal products that prolong the QTc interval, as the effects of adrenergic agonists on the cardiovascular system may be potentiated.

clarithromycin, vandetanib. Either increases the QTc toxicity of the other. Avoid or use alternative medicine. Avoid co-administration with drugs known to prolong the QT interval. If a drug known to prolong the QT interval is required, more frequent ECG monitoring is recommended.Clarithromycin will increase the level or effect of vandetanib by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine.

Clarithromycin and vardenafil increase the QTc interval. Avoid or use alternative medicine.

Vemurafenib and clarithromycin increase the QTc interval. Avoid or use alternative medicine. The concomitant use of vemurafenib with medicinal products that prolong the QT interval is not recommended. Clarithromycin may also increase vemurafenib levels.Clarithromycin will increase the level or effect of vemurafenib by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine.

Clarithromycin will increase the level or effect of venetoclax via the P-glycoprotein efflux transporter (MDR1). Avoid or use alternative medicine. If use of a P-gp inhibitor is necessary, reduce the dose of venetoclax by at least 50%. Watch more closely for signs of venetoclax toxicity.

Clarithromycin will increase the level or effect of venlafaxine by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine.

Clarithromycin increases the toxicity of inhaled vilanterol furoate/fluticasone during the QTc interval. Avoid or use alternative medicine. Use extreme caution when co-administering vilanterol with medicinal products that prolong the QTc interval, as the effects of adrenergic agonists on the cardiovascular system may be potentiated.

Clarithromycin increases vilazodone levels by affecting hepatic/intestinal metabolism of the CYP3A4 enzyme. Avoid or use alternative medicine. If intolerable side effects occur when co-administered with moderate CYP3A4 inhibitors, reduce the daily dose to 20 mg.

Clarithromycin increases vorapaxar levels by affecting hepatic/intestinal metabolism of the CYP3A4 enzyme. Avoid or use alternative medicine.

Clarithromycin will increase the level or effect of voriconazole by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine.

Clarithromycin and vorinostat increase the QTc interval. Avoid or use alternative medicine.

Voxelotor will increase the level or effect of clarithromycin by affecting the metabolism of the intestinal/hepatic enzyme CYP3A4. Avoid or use alternative medicine. Voxelotor increases systemic exposure to sensitive CYP3A4 substrates. Avoid co-administration with sensitive CYP3A4 substrates with a narrow therapeutic index. Consider reducing the dose of the sensitive CYP3A4 substrate if unavoidable.

Clarithromycin will increase the level or effect of voxilaprevir by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Avoid or use alternative medicine.

Clarithromycin will increase the level or effect of zavegepant intranasally by Others (see comment). Avoid or use alternative medicine. OATP1B3 inhibitors may cause a significant increase in systemic exposure to zavegepant (an OATP1B3 substrate).

Clarithromycin and ziprasidone increase the QTc interval. Avoid or use alternative medicine.

Clarithromycin will increase the level or effect of abemaciclib by affecting hepatic/intestinal CYP3A4 enzyme metabolism. Modify treatment/close monitoring. Strong CYP3A4 inhibitors increase plasma levels of abemaciclib and its metabolites. Dose reduction of abemaciclib is required. If a strong CYP3A4 inhibitor is discontinued, increase the abemaciclib dose before initiating treatment with the strong inhibitor.

Albuterol and clarithromycin increase the QTc interval. Use Attention/Display.

Clarithromycin will increase the level or effect of alfentanil by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Use Attention/Display.

Clarithromycin will increase the level or effect of alfuzosin by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Use Attention/Display.Clarithromycin and alfuzosin increase the QTc interval. Use Attention/Display.

Clarithromycin will increase the level or effect of alosetron by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Use Attention/Display.

Clarithromycin will increase the level or effect of amikacin via the P-glycoprotein efflux transporter (MDR1). Use Attention/Display.

Clarithromycin will increase the level or effect of amitriptyline via the P-glycoprotein efflux transporter (MDR1). Use Attention/Display.

Clarithromycin will increase the level or effect of amlodipine by affecting the metabolism of the intestinal/hepatic enzyme CYP3A4. Use Attention/Display. Increased activity of calcium channel blockers can cause hypotension, edema, decreased heart rate, and acute kidney injury due to decreased renal blood flow.

Clarithromycin will increase the level or effect of apalutamide by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Use Attention/Display. Co-administration of apalutamide with strong inhibitors of CYP3A4 or CYP2C8 does not require modification of the starting dose. However, a dose reduction may be necessary based on tolerability.

Arformoterol and clarithromycin increase the QTc interval. Use Attention/Display.

Clarithromycin will increase the level or effect of armodafinil by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Use Attention/Display.

Clarithromycin will increase the level or effect of atazanavir by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Use Attention/Display.

Clarithromycin will increase the level or effect of atogepant by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Modify treatment/close monitoring. The recommended dose of atogepant is 10 mg PO qd when co-administered with strong CYP3A4 inhibitors.

Azithromycin and clarithromycin increase the QTc interval. Use Attention/Display.

Clarithromycin will reduce the level or effect of valsalazide by altering the intestinal flora. Applies only to the oral form of both agents. Use Attention/Display.

Clarithromycin will reduce the level or effect of bazedoxifene/conjugated estrogens by altering the intestinal flora. Applies only to oral forms of hormones. Low risk of contraceptive failure. Modify treatment/close monitoring.Clarithromycin will increase the level or effect of bazedoxifene/conjugated estrogens via the P-glycoprotein efflux transporter (MDR1). Use Attention/Display.

Clarithromycin and bendacillin increase QTc interval Modify treatment/close monitoring. The ECG should be closely monitored.

Belzutifan will decrease the level or effect of clarithromycin by affecting the metabolism of the intestinal/hepatic enzyme CYP3A4. Modify treatment/close monitoring. If co-administration of belzutifan with sensitive CYP3A4 substrates cannot be avoided, consider increasing the dose of the sensitive CYP3A4 substrate in accordance with the prescribing information.

Clarithromycin will increase the level or effect of benzohydrocodone/acetaminophen by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Modify treatment/close monitoring. Co-administration with strong CYP3A4 inhibitors may increase plasma concentrations of hydrocodone (benzohydrocodone is a prodrug of hydrocodone) and may cause life-threatening respiratory depression.

Clarithromycin increases berotralstat levels via the P-glycoprotein efflux transporter (MDR1). Modify treatment/close monitoring. The berotralstat dose is decreased to 110 mg/day when co-administered with P-gp inhibitors.

Clarithromycin increases betrixaban levels via the P-glycoprotein efflux transporter (MDR1). Use Attention/Display. Reduce betrixaban dose to 80 mg PO once and then to 40 mg PO once daily if co-administered with a P-gp inhibitor.

Clarithromycin will increase the level or effect of bexarotene by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Use Attention/Display.

Clarithromycin will reduce the level or effect of biotin by altering the intestinal flora. Applies only to the oral form of both agents. Use Attention/Display.

Clarithromycin will increase the level or effect of bortezomib by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Use Attention/Display.

Clarithromycin will increase the level or effect of bosentan by affecting the metabolism of the intestinal/hepatic enzyme CYP3A4. Use Attention/Display.

Clarithromycin increases brentuximab vedotin levels by affecting hepatic/intestinal CYP3A4 enzyme metabolism. Use Attention/Display. Monitor patients for adverse effects. .

Clarithromycin will increase the level or effect of brexpiprazole by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Modify treatment/close monitoring. Give half the usual dose of brexpiprazole when co-administered with strong CYP3A4 inhibitors. If co-administered with a strong/moderate CYP2D6 inhibitor, administer a quarter dose of brexpiprazole.

Clarithromycin increases bromocriptine levels by decreasing metabolism. Use Attention/Display. Elevated levels possibly due to CYP3A4 inhibition.

Clarithromycin will increase the level or effect of budesonide via the P-glycoprotein efflux transporter (MDR1). Use Attention/Display.

Clarithromycin will increase the level or effect of buprenorphine subcutaneous implantation by affecting hepatic/intestinal CYP3A4 enzyme metabolism. Modify treatment/close monitoring. Monitor patients who already have a buprenorphine subcutaneous implant and require newly initiated therapy with CYP3A4 inhibitors for signs and symptoms of drug overuse. If the dose of the co-administered CYP3A4 inhibitor cannot be reduced or discontinued, the implant may need to be removed and the patient should then be treated with a dosage form of buprenorphine that allows for dose adjustments. If a CYP3A4 inhibitor is discontinued in a patient stabilized on buprenorphine, monitor the patient for withdrawal.

Clarithromycin will increase the level or effect of buprenorphine long-acting injection by affecting hepatic/intestinal CYP3A4 enzyme metabolism. Modify treatment/close monitoring. Patients transferred to long-acting injectable buprenorphine from transmucosal buprenorphine co-administered with CYP3A4 inhibitors should be monitored to ensure adequate buprenorphine plasma levels. Within 2 weeks, if signs and symptoms of buprenorphine toxicity or overdose occur and the concomitant CYP3A4 inhibitor cannot be reduced or discontinued, switch the patient back to a buprenorphine formulation that allows for dose adjustments.

clarithromycin, calcifediol. that affect the metabolism of the hepatic/intestinal enzyme CYP3A4. Modify treatment/close monitoring. CYP450 inhibitors can inhibit enzymes involved in vitamin D metabolism (CYP24A1 and CYP27B1). This can alter serum calcifediol levels and reduce the conversion of calcifediol to calcitriol. Calcifediol dose adjustment may be necessary and serum 25-hydroxyvitamin D, intact PTH, and serum calcium should be closely monitored when initiating or discontinuing a strong CYP3A4 inhibitor.

Clarithromycin will increase the level or effect of cannabidiol by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Modify treatment/close monitoring. Consider reducing the dose of cannabidiol when co-administered with a strong CYP3A4 inhibitor.

Clarithromycin will increase the level or effect of capatinib by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Use Attention/Display.

Clarithromycin will increase the level or effect of cariprazine by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Modify treatment/close monitoring. Co-administration with strong CYP3A4 inhibitors requires a dose reduction of cariprazine. See the Dose Modification section in the drug monograph.

Clarithromycin reduces the effects of cefdinir through pharmacodynamic antagonism. Use Attention/Display. Bacteriostatic agents can inhibit the effects of bactericidal agents.

Clarithromycin reduces the effects of cefditeren through pharmacodynamic antagonism. Use Attention/Display. Bacteriostatic agents can inhibit the effects of bactericidal agents.

Clarithromycin reduces the effects of cefoxitin through pharmacodynamic antagonism. Use Attention/Display. Bacteriostatic agents can inhibit the effects of bactericidal agents.

Clarithromycin reduces the effects of cefpodoxime through pharmacodynamic antagonism. Use Attention/Display. Bacteriostatic agents can inhibit the effects of bactericidal agents.

Clarithromycin reduces the effects of cefuroxime through pharmacodynamic antagonism. Use Attention/Display. Bacteriostatic agents can inhibit the effects of bactericidal agents.

Cenobamate will decrease the level or effect of clarithromycin by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Modify treatment/close monitoring. Increase the CYP3A4 substrate dose as needed when co-administered with kenobamate.

Clarithromycin increases ceritinib levels via the P-glycoprotein efflux transporter (MDR1). Use Attention/Display.

Clarithromycin will increase the level or effect of cevimeline by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Use Attention/Display.

Clarithromycin will increase the level or effect of chlordiazepoxide by affecting the metabolism of the intestinal/hepatic enzyme CYP3A4. Use Attention/Display.

Clarithromycin increases chlorpropamide levels by antagonizing binding to plasma proteins. Use Attention/Display. Risk of hypoglycemia.

Clarithromycin increases bile acid toxicity by reducing excretion. Modify treatment/close monitoring. Avoid concomitant use of bile salt efflux pump (BSEP) inhibitors. May aggravate accumulation of conjugated bile salts in the liver and cause clinical symptoms. If concomitant use is necessary, monitor serum transaminases and bilirubin.

Clarithromycin will increase the level or effect of inhaled ciclesonide by affecting hepatic/intestinal CYP3A4 enzyme metabolism. Use Attention/Display.

Cimetidine will increase the level or effect of clarithromycin by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Use Attention/Display.Clarithromycin will increase the level or effect of cimetidine on the P-glycoprotein efflux transporter (MDR1). Use Attention/Display.

Clarithromycin will increase the level or effect of clevidipine by affecting the hepatic/intestinal metabolism of the CYP3A4 enzyme. Use Attention/Display. Increased activity of calcium channel blockers can cause hypotension, edema, decreased heart rate, and acute kidney injury due to decreased renal blood flow.

Clarithromycin will increase the level or effect of clonazepam by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Use Attention/Display.

Clarithromycin will increase the level or effect of clorazepate by affecting the metabolism of the intestinal/hepatic enzyme CYP3A4. Use Attention/Display.

Clarithromycin will reduce the level or effect of conjugated estrogens by altering the intestinal flora. Applies only to oral forms of hormones. Low risk of contraceptive failure. Modify treatment/close monitoring.Clarithromycin will increase the level or effect of estrogens conjugated by the P-glycoprotein efflux transporter (MDR1). Use Attention/Display.

Clarithromycin will increase the level or effect of conjugated estrogens, freely via the P-glycoprotein efflux transporter (MDR1). Use Attention/Display.

Clarithromycin will increase the level or effect of cortisone via the P-glycoprotein efflux transporter (MDR1). Use Attention/Display.

Clarithromycin increases crizotinib levels by affecting hepatic/intestinal metabolism of the CYP3A4 enzyme. Use Attention/Display. Concomitant use of strong CYP3A inhibitors should be avoided. ECG monitoring is recommended, along with medications that may prolong the QT interval.

Crofelemer increases clarithromycin levels by affecting the metabolism of the intestinal/hepatic enzyme CYP3A4. Use Attention/Display. Crofelemer has the potential to inhibit CYP3A4 at expected concentrations in the intestine. It will hardly be systemically inhibited because it is poorly absorbed.

Clarithromycin will increase the level or effect of cyclosporine via the P-glycoprotein efflux transporter (MDR1). Use Attention/Display.

Clarithromycin will increase the level or effect of dabigatran via the P-glycoprotein efflux transporter (MDR1). Use Attention/Display. Atrial fibrillation: Avoid co-administration of dabigatran with P-gp inhibitors if CrCl <30 mL/min. Treatment of DVT/PE: Avoid co-administration of dabigatran with P-gp inhibitors if CrCl < 50 mL/min.

Dabrafenib will decrease the level or effect of clarithromycin by affecting the metabolism of the intestinal/hepatic enzyme CYP3A4. Modify treatment/close monitoring.

Clarithromycin will increase the level or effect of dapsone by affecting the metabolism of the intestinal/hepatic enzyme CYP3A4. Use Attention/Display.

Clarithromycin will increase the level or effect of darolutamide of the Other (see comment). Modify treatment/close monitoring. Darolutamide is a substrate of P-gp and CYP3A4. Closely monitor the increase in adverse effects and modify the dose of darolutamide as necessary when co-administered with medicinal products that are both strong or moderate inhibitors of P-gp and CYP3A4.

Clarithromycin will increase the level or effect of darunavir by affecting the metabolism of the intestinal/hepatic enzyme CYP3A4. Modify treatment/close monitoring. Consider alternative antibiotics if clarithromycin is co-administered with darunavir (plus ritonavir or cobicistat). If clarithromycin is required, no dose adjustment is necessary with normal renal function. However, reduce the clarithromycin dose by 50% with CrCl 30-60 mL/min and by 75% with CrCl <30 mL/min.Darunavir increases clarithromycin levels by decreasing metabolism. Use Attention/Display. Dose adjustments are not required for normal renal function. If CrCl = 30 60 ml/min, reduce the clarithromycin dose by 50%. If CrCl < 30 mL/min, reduce the clarithromycin dose by 75%.

Clarithromycin and dasatinib increase QTc interval Modify treatment/close monitoring.

Clarithromycin will increase the level or effect of daunorubicin via the P-glycoprotein efflux transporter (MDR1). Use Attention/Display.

Deferasirox will decrease the level or effect of clarithromycin by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Use Attention/Display.

Clarithromycin will increase the level or effect of deflazacort by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Modify treatment/close monitoring. Reduce deflazacort dose to one third of the recommended dose if co-administered with moderate or strong CYP3A4 inhibitors.Clarithromycin will increase the level or effect of deflazacort via the P-glycoprotein efflux transporter (MDR1). Use Attention/Display.

Clarithromycin and deutetrabenazine increase the QTc interval. Use Attention/Display. At the maximum recommended dose, deutetrabenazine does not clinically significantly prolong the QT interval. Certain circumstances may increase the risk of torsades de pointes and/or sudden death in combination with drugs that prolong the QTc interval (eg, bradycardia, hypokalemia or hypomagnesemia, co-administration with other drugs that prolong the QTc interval, presence of congenital prolongation of the QTcQT).

Clarithromycin will increase the level or effect of dexamethasone via the P-glycoprotein efflux transporter (MDR1). Use Attention/Display.

Clarithromycin will increase the level or effect of intranasal diazepam by affecting hepatic/intestinal CYP3A4 enzyme metabolism. Use Attention/Display. Strong or moderate CYP3A4 inhibitors may decrease the rate of diazepam elimination, thereby increasing the adverse effects of diazepam.

Clarithromycin will increase the level or effect of dienogest/estradiol valerate by affecting hepatic/intestinal CYP3A4 enzyme metabolism. Use Attention/Display. Watch for possible side effects such as nausea, irregular uterine bleeding, breast tenderness, and headache.Clarithromycin will reduce the level or effect of dienogest/estradiol valerate by altering the intestinal flora. Applies only to oral forms of hormones. Low risk of contraceptive failure. Use Attention/Display. An alternative or additional form of contraception may be recommended during concomitant use.

Clarithromycin will increase the level or effect of digoxin on the P-glycoprotein efflux transporter (MDR1). Use Attention/Display.

Clarithromycin will increase the level or effect of diltiazem by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Use Attention/Display. Increased activity of calcium channel blockers can cause hypotension, edema, decreased heart rate, and acute kidney injury due to decreased renal blood flow.

Clarithromycin will increase the level or effect of disopyramide by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Use Attention/Display.

Clarithromycin will increase the level or effect of docetaxel by affecting the hepatic/intestinal metabolism of the CYP3A4 enzyme. Use Attention/Display.Clarithromycin will increase the level or effect of docetaxel via the P-glycoprotein efflux transporter (MDR1). Use Attention/Display.

Clarithromycin and dolasetron increase QTc interval Modify treatment/close monitoring.

Clarithromycin will increase the level or effect of donepezil by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Use Attention/Display.

Clarithromycin will increase the level or effect of doravirine by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Use Attention/Display. Co-administration of doravirine and CYP3A4 inhibitors may increase doravirine plasma concentrations and toxicity.

Clarithromycin will increase the level or effect of doxepin cream by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Use Attention/Display.

Clarithromycin will increase the level or effect of doxorubicin by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Use Attention/Display.Clarithromycin will increase the level or effect of doxorubicin via the P-glycoprotein efflux transporter (MDR1). Use Attention/Display.

Clarithromycin will increase the level or effect of liposomal doxorubicin by affecting hepatic/intestinal CYP3A4 enzyme metabolism. Use Attention/Display.Clarithromycin will increase the level or effect of liposomal doxorubicin via the P-glycoprotein efflux transporter (MDR1). Use Attention/Display.

Clarithromycin will increase the level or effect of dronabinol by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Use Attention/Display. Dronabinol is a CYP3A4 substrate.

Clarithromycin will increase the level or effect of dutasteride by affecting hepatic/intestinal CYP3A4 enzyme metabolism. Use Attention/Display.

Clarithromycin will increase the level or effect of duvelisib by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Modify treatment/close monitoring. Co-administration with a strong CYP3A4 inhibitor increases the AUC of duvelisib, which may increase the risk of duvelisib toxicity. Reduce the duvelisib dose to 15 mg twice daily when co-administered with a strong CYP3A4 inhibitor.Duvelisib will increase the level or effect of clarithromycin by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Modify treatment/close monitoring. will increase its level or effectClarithromycin will increase the level or effect of duvelisib via the P-glycoprotein efflux transporter (MDR1). Use Attention/Display.

Clarithromycin will increase the level or effect of efavirenz by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Use Attention/Display.

Clarithromycin will increase the level or effect of elagolix by affecting the metabolism of the intestinal/hepatic enzyme CYP3A4. Modify treatment/close monitoring. Co-administration of elagolix 200 mg daily with strong CYP3A inhibitors for >1 month is not recommended. Limit elagolix dose to 150 mg per day and duration of CYP3A inhibitor use to 6 months if co-administered.Elagolix will decrease the level or effect of clarithromycin by affecting the metabolism of the intestinal/hepatic enzyme CYP3A4. Modify treatment/close monitoring. Elagolix is ​​a weak to moderate inducer of CYP3A4. Monitor CYP3A substrates if co-administered. Consider increasing the CYP3A substrate dose if necessary.

Clarithromycin increases elvitegravir levels by affecting hepatic/intestinal metabolism of the CYP3A4 enzyme. Use Attention/Display. Elvitegravir is a CYP3A4 substrate. if co-administered with strong CYP3A4 inhibitors, levels may be increased.

elvitegravir/combicistat/emtricitabine/tenofovir DF, clarithromycin. Either one increases the levels of the other, affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Modify treatment/close monitoring. Concentrations of clarithromycin and/or cobicistat may be increased. reduce clarithromycin dose by 50% if CrCl <60 mL/min.

encorafenib, clarithromycin. that affect the metabolism of the hepatic/intestinal enzyme CYP3A4. Use Attention/Display. Encorafenib inhibits and induces CYP3A4 at clinically relevant plasma concentrations. Co-administration of encorafenib with sensitive CYP3A4 substrates may result in increased toxicity or decreased efficacy of these agents.

Clarithromycin increases the toxicity of enfortumab vedotin by affecting hepatic/intestinal metabolism of the CYP3A4 enzyme. Use Attention/Display. Enfortumab vedotin is an antibody-drug conjugate that releases monomethylauristatin E (MMAE) by proteolytic cleavage. MMAE is primarily metabolized by CYP3A4 in vitro. Co-administration with strong CYP3A4 inhibitors may increase exposure to free MMAE, which may increase the incidence or severity of toxicities.Clarithromycin will increase the level or effect of enfortumab vedotin by others (see comment). Use Attention/Display. Co-administration with dual P-gp inhibitors and strong CYP3A4 inhibitors may increase unconjugated small molecule microtubule monomethyl auristatin E (MMAE) exposure, which may increase the risk of enfortumab vedotin toxicity. Monitor closely for signs of toxicity.

Enzalutamide will decrease the level or effect of clarithromycin by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Use Attention/Display.

Clarithromycin will increase the level or effect of eplerenone by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Use Attention/Display.

Clarithromycin will increase the level or effect of erlotinib via the P-glycoprotein efflux transporter (MDR1). Use Attention/Display.

Clarithromycin will increase the level or effect of background erythromycin by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Use Attention/Display.Erythromycin base will increase the level or effect of clarithromycin by affecting hepatic/intestinal CYP3A4 enzyme metabolism. Use Attention/Display.

Erythromycin ethylsuccinate will increase the level or effect of clarithromycin by affecting hepatic/intestinal CYP3A4 enzyme metabolism. Use Attention/Display.

Erythromycin lactobionate will increase the level or effect of clarithromycin by affecting hepatic/intestinal CYP3A4 enzyme metabolism. Use Attention/Display.

Erythromycin stearate will increase the level or effect of clarithromycin by affecting hepatic/intestinal CYP3A4 enzyme metabolism. Use Attention/Display.

Clarithromycin will reduce the level or effect of estradiol by altering the intestinal flora. Applies only to oral forms of hormones. Low risk of contraceptive failure. Modify treatment/close monitoring.Clarithromycin will increase the level or effect of estradiol via the P-glycoprotein efflux transporter (MDR1). Use Attention/Display.

Clarithromycin will increase the level or effect of vaginal estradiol by affecting hepatic/intestinal CYP3A4 enzyme metabolism. Use Attention/Display. Co-administration with CYP3A4 inhibitors may increase plasma estrogen concentrations and toxicity.

Clarithromycin will reduce the level or effect of synthetic conjugated estrogens by altering the intestinal flora. Applies only to oral forms of hormones. Low risk of contraceptive failure. Modify treatment/close monitoring.Clarithromycin will increase the level or effect of synthetic estrogens conjugated to the P-glycoprotein efflux transporter (MDR1). Use Attention/Display.

Clarithromycin will increase the level or effect of esterified estrogens by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Use Attention/Display.

Clarithromycin will reduce the level or effect of estropipate by altering the intestinal flora. Applies only to oral forms of hormones. Low risk of contraceptive failure. Modify treatment/close monitoring.Clarithromycin will increase the level or effect of the eotrope through the P-glycoprotein efflux transporter (MDR1). Use Attention/Display.

Clarithromycin increases eszopiclone levels by increasing gastrointestinal absorption. Applies only to the oral form of both agents. Use Attention/Display.Clarithromycin increases eszopiclone levels by affecting the metabolism of the intestinal/hepatic enzyme CYP3A4. Modify treatment/close monitoring. Reduce the starting dose of eszopiclone to 1 mg/day.

Clarithromycin will reduce the level or effect of ethinyl estradiol by altering the intestinal flora. Applies only to oral forms of hormones. Low risk of contraceptive failure. Modify treatment/close monitoring.

Clarithromycin will increase the level or effect of etoposide by affecting the hepatic/intestinal metabolism of the CYP3A4 enzyme. Use Attention/Display.Clarithromycin will increase the level or effect of etoposide via the P-glycoprotein efflux transporter (MDR1). Use Attention/Display.

Clarithromycin will increase the level or effect of eucalyptus by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Use Attention/Display.

ezogabine, clarithromycin. Either increases the QTc toxicity of the other. Use Attention/Display. Mild and transient prolongation of the QT interval was observed with ezgambine, particularly when the dose was titrated to 1200 mg/day. The QT interval should be monitored when ezogambine is prescribed with agents known to increase the QT interval.

Fedratinib will increase the level or effect of clarithromycin by affecting hepatic/intestinal CYP3A4 enzyme metabolism. Use Attention/Display. Adjust the dose of drugs that are CYP3A4 substrates as needed.

Clarithromycin will increase the level or effect of felodipine by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Use Attention/Display. Increased activity of calcium channel blockers can cause hypotension, edema, decreased heart rate, and acute kidney injury due to decreased renal blood flow.

Clarithromycin will increase the level or effect of finasteride by affecting the metabolism of the intestinal/hepatic enzyme CYP3A4. Use Attention/Display.

Clarithromycin and flecainide increase QTc interval Modify treatment/close monitoring.

Clarithromycin will increase the level or effect of fludrocortisone via the P-glycoprotein efflux transporter (MDR1). Use Attention/Display.

Clarithromycin and fluoxetine increase QTc interval Modify treatment/close monitoring.

Clarithromycin will increase the level or effect of flurazepam by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Use Attention/Display.

Clarithromycin will increase the level or effect of fluticasone furoate by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Use Attention/Display. Strong CYP3A4 inhibitors may increase systemic exposure to fluticasone

Clarithromycin will increase the level or effect of inhaled fluticasone by affecting hepatic/intestinal CYP3A4 enzyme metabolism. Use Attention/Display. Strong CYP3A4 inhibitors may increase systemic exposure to fluticasone

Fluvoxamine and clarithromycin increase QTc interval Modify treatment/close monitoring.

Clarithromycin and foscarnet increase QTc interval Modify treatment/close monitoring.

Clarithromycin will increase the level or effect of fostamatinib by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Modify treatment/close monitoring. Strong CYP3A4 inhibitors may increase exposure to R406 (fostamatinib's major active metabolite). Monitor for toxicities that may require a dose reduction of fostamatinib.

Clarithromycin will increase the level or effect of galantamine by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Use Attention/Display.

Clarithromycin increases gefitinib levels by affecting hepatic/intestinal CYP3A4 enzyme metabolism. Modify treatment/close monitoring. Co-administration of strong CYP3A4 inhibitors may increase the risk of adverse effects of gefitinib.

Clarithromycin and gemtuzumab increase the QTc interval. Use Attention/Detection.

Clarithromycin will increase the level or effect of gentamicin via the P-glycoprotein efflux transporter (MDR1). Use Attention/Display.

Clarithromycin will increase the level or effect of glecaprevir/pibrentasvir by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Use Attention/Display.

Clarithromycin increases glimepiride levels by antagonizing binding to plasma proteins. Use Attention/Display. Risk of hypoglycemia.

Clarithromycin increases glipizide levels by antagonizing binding to plasma proteins. Use Attention/Display. Risk of hypoglycemia.

Clarithromycin increases glibenclamide levels by antagonizing binding to plasma proteins. Use Attention/Display. Risk of hypoglycemia.

Goserelin increases the toxicity of clarithromycin during the QTc interval. Use Attention/Display. Increases the risk of torsades de pointes.

Clarithromycin will increase the level or effect of guanfacine by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Modify treatment/close monitoring. Strong or moderate CYP3A4 inhibitors significantly increase guanfacine plasma concentrations. The FDA-approved labeling for extended-release (ER) guanfacine recommends that, if co-administered, the guanfacine dose be reduced to half the recommended dose. There are no specific recommendations for immediate-release (IR) guanfacine.

Histelin increases the toxicity of clarithromycin during the QTc interval. Use Attention/Display. Increases the risk of torsades de pointes.

Clarithromycin will increase the level or effect of hydrocodone by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Modify treatment/close monitoring. Co-administration with CYP3A4 inhibitors may increase hydrocodone plasma concentrations and cause life-threatening respiratory depression.

Clarithromycin will increase the level or effect of hydrocortisone via the P-glycoprotein efflux transporter (MDR1). Use Attention/Display.

Hydroxyzine increases the toxicity of clarithromycin during the QTc interval. Use Attention/Display. Increases the risk of torsades de pointes.

Clarithromycin will decrease the level or effect of ifosfamide by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Modify treatment/close monitoring. Co-administration of CYP3A4 inhibitors may decrease the metabolism of ifosfamide to its active alkylating metabolites and decrease the efficacy of ifosfamide.

Clarithromycin and iloperidone increase QTc interval Modify treatment/close monitoring.Iloperidone increases clarithromycin levels by affecting the metabolism of the intestinal/hepatic enzyme CYP3A4. Use Attention/Display. Iloperidone is a time-dependent CYP3A inhibitor and may cause increased plasma levels of drugs that are primarily cleared by CYP3A4.

Clarithromycin will increase the level or effect of imatinib by affecting the hepatic/intestinal metabolism of the CYP3A4 enzyme. Use Attention/Display.Clarithromycin will increase the level or effect of imatinib via the P-glycoprotein efflux transporter (MDR1). Use Attention/Display.

Clarithromycin increases the levels of indacaterol inhaled by other people (see comment). Use Attention/Display. Comment: Data suggest that systemic clearance is affected by regulation of P-gp and CYP3A4 activity. No dose adjustments are needed with the 75 mcg dose.indacaterol, inhaled, clarithromycin. QTc interval Use Attention/Display. Drugs known to prolong the QTc interval may have an increased risk of ventricular arrhythmias.

Clarithromycin will increase the level or effect of indinavir via the P-glycoprotein efflux transporter (MDR1). Use Attention/Display.

Isoniazid will increase the level or effect of clarithromycin by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Modify treatment/close monitoring.

Clarithromycin will increase the level or effect of isradipine by affecting the hepatic/intestinal metabolism of the CYP3A4 enzyme. Use Attention/Display. Increased activity of calcium channel blockers can cause hypotension, edema, decreased heart rate, and acute kidney injury due to decreased renal blood flow.

Clarithromycin will increase the level or effect of istradefylline by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Modify treatment/close monitoring. Do not exceed 20 mg istradefylline/day if co-administered with strong CYP3A4 inhibitors.Istradefylline will increase the level or effect of clarithromycin by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Use Attention/Display. Istradefylline 40 mg/day increased the peak levels and AUC of CYP3A4 substrates in clinical trials. This effect was not seen with istradefylline 20 mg/day. Consider reducing the dose of sensitive CYP3A4 substrates.

Clarithromycin will increase the level or effect of itraconazole by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Use Attention/Display.Clarithromycin and itraconazole increase the QTc interval. Use Attention/Control.

Clarithromycin will increase the level or effect of ivacaftor by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Modify treatment/close monitoring. Reduce ivacaftor dose if co-administered with strong CYP3A4 inhibitors. Please refer to the specific product containing ivacaftor to change the exact dose.

Clarithromycin will increase the level or effect of ivermectin through the P-glycoprotein efflux transporter (MDR1). Use Attention/Display.

Clarithromycin will increase the level or effect of ketoconazole by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Use Attention/Display.

Clarithromycin increases lacosamide levels by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Modify treatment/close monitoring. Consider a dose reduction of lacosamide when co-administered with strong CYP3A4 inhibitors.

Clarithromycin will increase the level or effect of lansoprazole by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Use Attention/Display.

Clarithromycin will increase the level or effect of lapatinib via the P-glycoprotein efflux transporter (MDR1). Use Attention/Display.Clarithromycin and lapatinib increase QTc interval Modify treatment/close monitoring.

Lencapavir will increase the level or effect of clarithromycin by affecting the metabolism of the intestinal/hepatic enzyme CYP3A4. Use Attention/Display. Lencapavir (a moderate CYP3A4 inhibitor) may increase CYP3A4 substrates initiated within 9 months of the last SC dose of lencapavir, which may increase the potential risk of CYP3A4 substrate adverse effects.

Clarithromycin and lenvatinib increase the QTc interval. Use Attention/Display. The lenvatinib prescribing information recommends close ECG monitoring when co-administered with drugs that prolong the QT interval.

Clarithromycin increases letermovir levels by decreasing metabolism. Use Attention/Display. Co-administration of letermovir, an OATP1B1/3 substrate, with OATP1B1/3 inhibitors may increase letermovir plasma concentrations.

Leuprolide increases the toxicity of clarithromycin during the QTc interval. Use Attention/Detection. Increases the risk of torsades de pointes.

Clarithromycin and levalbuterol increase the QTc interval. Use Attention/Display.

Clarithromycin will increase the level or effect of levamlodipine by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Modify treatment/close monitoring. Co-administration with moderate and strong CYP3A inhibitors results in increased systemic exposure to amlodipine and may require a dose reduction. Monitor symptoms of hypotension and edema when amlodipine is co-administered with CYP3A inhibitors to determine the need for dose adjustment.

Clarithromycin and levofloxacin increase QTc interval Modify treatment/close monitoring.

Clarithromycin will increase the level or effect of levoketoconazole by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Use Attention/Display.

Clarithromycin will increase the level or effect of levomilnacipran by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Modify treatment/close monitoring. Do not exceed 80 mg/day levomilnacipran when co-administered with strong CYP3A4 inhibitors.

Clarithromycin will decrease the level or effect of oral levonorgestrel/ethinylestradiol/iron diglycinate by altering the intestinal flora. Applies only to oral forms of hormones. Low risk of contraceptive failure. Use Attention/Display. Antibiotics can reduce the effectiveness of hormonal contraceptives.Clarithromycin will increase the level or effect of oral levonorgestrel/ethinylestradiol/ferric diglycinate by affecting hepatic/intestinal CYP3A4 enzyme metabolism. Use Attention/Display. Co-administration with CYP3A4 inhibitors may increase plasma concentrations of the hormone. It is recommended to use a non-hormonal contraceptive.

Clarithromycin will increase the level or effect of loperamide via the P-glycoprotein efflux transporter (MDR1). Use Attention/Display.

Clarithromycin increases lumacaftor/ivacaftor levels by affecting the metabolism of the intestinal/hepatic enzyme CYP3A4. Modify treatment/close monitoring. Strong CYP3A inhibitors do not affect lumacaftor exposure, but increase ivacaftor exposure 4.3-fold. Due to the CYP3A-inducing effect of lumacaftor, at steady-state the net exposure of ivacaftor is not expected to exceed that given in the absence of lumacaftor at a dose of 150 mg every 12 hours (the approved ivacaftor monotherapy dose). Therefore, no dose adjustment is necessary when initiating CYP3A inhibitor therapy in patients currently receiving lumacaftor/ivacaftor. However, when initiating lumacaftor/ivacaftor in patients treated with strong CYP3A inhibitors, reduce the dose to 1 tablet per day (lumacaftor 200 mg/ivacaftor 125 mg total daily dose) during the first week of treatment to allow the dose to stabilize. lumacaftor induction effect. . After this period, continue with the recommended daily dose. No dose adjustment is required for moderate or weak CYP3A4 inhibitors.

Clarithromycin will increase the level or effect of lumateperone by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Modify treatment/close monitoring. Reduce the lumateperone dose to 10.5 mg/day if co-administered with strong CYP3A4 inhibitors.

Clarithromycin will increase the level or effect of maraviroc by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Use Attention/Display. Reduce maraviroc dose to 150 mg twice daily when co-administered with strong CYP3A4 inhibitors.Clarithromycin will increase the level or effect of maraviroc via the P-glycoprotein efflux transporter (MDR1). Use Attention/Display.

Clarithromycin will increase the level or effect of marijuana by affecting the metabolism of the liver/gut enzyme CYP3A4. Use Attention/Display.

Clarithromycin will increase the level or effect of medroxyprogesterone by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Use Attention/Display.

Clarithromycin will reduce the level or effect of mestranol by altering the intestinal flora. Applies only to oral forms of hormones. Low risk of contraceptive failure. Modify treatment/close monitoring.Clarithromycin will increase the level or effect of mestranol via the P-glycoprotein efflux transporter (MDR1). Use Attention/Display.

Clarithromycin and methadone increase QTc interval Modify treatment/close monitoring.

Clarithromycin will increase the level or effect of methylprednisolone on the P-glycoprotein efflux transporter (MDR1). Use Attention/Display.

Clarithromycin will increase the level or effect of mifepristone by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Modify treatment/close monitoring. Do not exceed 300 mg mifepristone for Cushing's syndrome when co-administered with strong CYP3A4 inhibitors. The combination can also prolong the QT interval. Use alternatives if available

Clarithromycin will increase the level or effect of mirvetuximab soravtansin by affecting hepatic/intestinal CYP3A4 enzyme metabolism. Use Attention/Display. Co-administration with strong CYP3A4 inhibitors may increase exposure to unconjugated DM4 (a substrate of CYP3A4 and the cytotoxic component of mirvetuximab soravtansine antibody-drug conjugate), which may increase the risk of adverse effects.

Mitotane decreases clarithromycin levels by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Use Attention/Display. Mitotane is a potent inducer of cytochrome P-4503A4. monitor when co-administered with CYP3A4 substrates for possible dose adjustments.

Clarithromycin will increase the level or effect of inhaled mometasone by affecting hepatic/intestinal CYP3A4 enzyme metabolism. Use Attention/Display. Increases riak for side effects of systemic corticosteroids.

Clarithromycin will increase the level or effect of intranasal mometasone by affecting hepatic/intestinal CYP3A4 enzyme metabolism. Use Attention/Display.

Clarithromycin will increase the level or effect of montelukast by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Use Attention/Display.

Clarithromycin increases naldemedine levels by affecting the metabolism of the intestinal/hepatic enzyme CYP3A4. Use Attention/Display. Monitor naldemedine for possible adverse effects if co-administered with strong or moderate CYP3A4 inhibitors.Clarithromycin increases levels of the P-glycoprotein efflux transporter naldimedine (MDR1). Use Attention/Display. Monitor naldemedine for potential adverse effects if co-administered with P-gp inhibitors.

Clarithromycin decreases nateglinide levels by affecting hepatic/intestinal metabolism of the CYP3A4 enzyme. Use Attention/Display. May cause hypoglycemia. Closely monitor glucose levels.

Clarithromycin will increase the level or effect of nelfinavir via the P-glycoprotein efflux transporter (MDR1). Use Attention/Display.

Clarithromycin will increase the level or effect of neomycin PO via the P-glycoprotein efflux transporter (MDR1). Use Attention/Display.

Clarithromycin will increase the level or effect of netupitan/palonosetron by affecting hepatic/intestinal CYP3A4 enzyme metabolism. Use Attention/Display. Netupitat is mainly metabolized by CYP3A4. It is not necessary to adjust the dose

Clarithromycin will increase the level or effect of nicardipine by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Use Attention/Display. Increased activity of calcium channel blockers can cause hypotension, edema, decreased heart rate, and acute kidney injury due to decreased renal blood flow.

Clarithromycin will increase the level or effect of nifedipine by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Use Attention/Display. Increased action of calcium channel blockers can cause hypotension, edema, decreased heart rate, and acute kidney injury due to decreased renal blood flow. consider starting nifedipine at the lowest available dose if co-administered with this drug

Clarithromycin will increase the level or effect of nilotinib via the P-glycoprotein efflux transporter (MDR1). Use Attention/Display.

Clarithromycin will increase the level or effect of nimodipine by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Use Attention/Display. Increased activity of calcium channel blockers can cause hypotension, edema, decreased heart rate, and acute kidney injury due to decreased renal blood flow.

Clarithromycin increases nintedanib levels via the P-glycoprotein efflux transporter (MDR1). Modify treatment/close monitoring. If adverse effects of nintedanib occur, treatment may require interruption, dose reduction, or discontinuation of treatment.

Nirmatrelvir will increase the level or effect of clarithromycin by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Modify treatment/close monitoring. Do not exceed clarithromycin doses >1000 mg/day in patients receiving protease inhibitors. Consider reducing the clarithromycin dose in patients with renal insufficiency.

Nirmatrelvir/ritonavir will increase the level or effect of clarithromycin by affecting the hepatic/intestinal metabolism of the CYP3A4 enzyme. Modify treatment/close monitoring. Do not exceed clarithromycin doses >1000 mg/day in patients receiving protease inhibitors. Consider reducing the clarithromycin dose in patients with renal insufficiency.

Clarithromycin will increase the level or effect of nisoldipine by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Use Attention/Display. Increased activity of calcium channel blockers can cause hypotension, edema, decreased heart rate, and acute kidney injury due to decreased renal blood flow.

Clarithromycin will increase the level or effect of nitrendipine by affecting the hepatic/intestinal metabolism of the CYP3A4 enzyme. Use Attention/Display.

Clarithromycin will increase the level or effect of norgestrel by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Use Attention/Display. Strong or moderate CYP3A4 inhibitors may increase the systemic concentration of norgestrel, which may increase the risk of adverse effects.

Clarithromycin and ofloxacin increase QTc interval Modify treatment/close monitoring.

Clarithromycin will increase the level or effect of oliceridin by affecting the hepatic/intestinal metabolism of the CYP3A4 enzyme. Modify treatment/close monitoring. If concomitant use is necessary, less frequent administration of oliceridin may be necessary. Monitor closely for respiratory depression and sedation and adjust subsequent doses accordingly. If the inhibitor is discontinued, consider increasing the oliceridin dose until stable drug effects are achieved. Watch for signs of opioid withdrawal.

Clarithromycin and inhaled olodaterol increase the QTc interval. Use Attention/Display. Drugs that prolong the QTc interval and may potentiate the effects of beta2-agonists on the cardiovascular system. increased risk of ventricular arrhythmias

Clarithromycin will increase the level or effect of osilodrostat by affecting hepatic/intestinal CYP3A4 enzyme metabolism. Modify treatment/close monitoring. Halve the dose of osilodrostat, a CYP3A4 substrate, when co-administered with a strong CYP3A4 inhibitor.Osilodrostat and clarithromycin increase the QTc interval. Use Attention/Display.

Osimertinib and clarithromycin increase the QTc interval. Use Attention/Display. Perform regular ECG and electrolyte checks in patients receiving drugs known to prolong the QTc interval.

Clarithromycin increases ospemifene levels by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Use Attention/Display.

Oxaliplatin will increase the level or effect of clarithromycin of the Other (see comment). Use Attention/Display. Monitor ECG changes if treatment is initiated in patients taking drugs known to prolong the QT interval.

Clarithromycin will increase the level or effect of oxybutynin by affecting hepatic/intestinal CYP3A4 enzyme metabolism. Use Attention/Display.

Ozanimod and clarithromycin increase QTc interval Modify treatment/close monitoring. Due to potential additive effects on heart rate, ozanimod therapy should generally not be initiated in patients receiving concomitant QT-prolonging drugs with known arrhythmogenic properties.

Clarithromycin will increase the level or effect of paclitaxel by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Use Attention/Display.Clarithromycin will increase the level or effect of paclitaxel via the P-glycoprotein efflux transporter (MDR1). Use Attention/Display.

Clarithromycin will increase the level or effect of protein-bound paclitaxel by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Use Attention/Display.Clarithromycin will increase the level or effect of the protein paclitaxel that binds to the P-glycoprotein efflux transporter (MDR1). Use Attention/Display.

Clarithromycin will increase the level or effect of paliperidone via the P-glycoprotein efflux transporter (MDR1). Use Attention/Display.Clarithromycin and paliperidone increase QTc interval Modify treatment/close monitoring.

Clarithromycin increases panobinostat levels by affecting the metabolism of the intestinal/hepatic enzyme CYP3A4. Modify treatment/close monitoring. Reduce the starting dose of panobinostat to 10 mg if co-administered with strong CYP3A4 inhibitors.

Clarithromycin will reduce the level or effect of pantothenic acid by altering the intestinal flora. Applies only to the oral form of both agents. Use Attention/Display.

Clarithromycin will increase the level or effect of parecoxib by affecting the metabolism of the intestinal/hepatic enzyme CYP3A4. Use Attention/Display.

Clarithromycin will increase the level or effect of paricalcitol by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Use Attention/Display.

Clarithromycin will increase the level or effect of paromomycin via the P-glycoprotein efflux transporter (MDR1). Use Attention/Display.

Clarithromycin and paroxetine increase QTc interval Modify treatment/close monitoring.

Clarithromycin and pasireotide increase QTc interval Modify treatment/close monitoring.

Clarithromycin and pazopanib increase the QTc interval. Use Attention/Display.

Clarithromycin will increase the level or effect of perapanel by affecting the metabolism of the intestinal/hepatic enzyme CYP3A4. Use Attention/Display.

Clarithromycin will increase the level or effect of pimozide by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Use Attention/Display.

Clarithromycin will increase the level or effect of pioglitazone by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Use Attention/Display.

Clarithromycin reduces the effects of piperacillin through pharmacodynamic antagonism. Use Attention/Display. Bacteriostatic agents can inhibit the effects of bactericidal agents.

Clarithromycin increases the toxicity of pitavastatin by others (see comment). Use Attention/Display. Comment: OATP1B1 inhibitors may increase the risk of myopathy.

Clarithromycin will increase the level or effect of polatuzumab vedotin by affecting hepatic/intestinal CYP3A4 enzyme metabolism. Use Attention/Display. Polatuzumab is catabolized into small peptides, amino acids, monomethyl auristatin E (MMAE), and MMAE-related unconjugated catabolites. MMAE is a substrate of CYP3A4. Co-administration of polatuzumab vedotin with a strong CYP3A4 inhibitor may increase the AUC of unconjugated MMAE, which may increase the toxicity of polatuzumab vedotin.

Clarithromycin will increase the level or effect of posaconazole via the P-glycoprotein efflux transporter (MDR1). Use Attention/Display.Clarithromycin and posaconazole increase QTc interval Modify treatment/close monitoring.

Clarithromycin increases pravastatin levels by affecting hepatic/intestinal metabolism of the CYP3A4 enzyme. Use Attention/Display. Myopathy monitoring. do not exceed a pravastatin dose of 40 mg/day when co-administered with clarithromycin.Clarithromycin increases the toxicity of pravastatin in others (see comment). Use Attention/Display. Comment: OATP1B1 inhibitors may increase the risk of myopathy.

Clarithromycin will increase the level or effect of praziquantel by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Use Attention/Display.

Clarithromycin will increase the level or effect of prednisolone by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Use Attention/Display.Clarithromycin will increase the level or effect of prednisolone via the P-glycoprotein efflux transporter (MDR1). Use Attention/Display.

Clarithromycin will increase the level or effect of prednisone via the P-glycoprotein efflux transporter (MDR1). Use Attention/Display.Clarithromycin increases prednisone levels by slowing metabolism. Use Attention/Display. Risk of toxic concentrations of steroids and altered mental status.

Clarithromycin will increase the level or effect of propafenone by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Use Attention/Display.

Clarithromycin will reduce the level or effect of pyridoxine by altering the intestinal flora. Applies only to the oral form of both agents. Use Attention/Display.

Clarithromycin will reduce the level or effect of pyridoxine (antidote) by altering the intestinal flora. Applies only to the oral form of both agents. Use Attention/Display.

Clarithromycin will increase the level or effect of cazepam by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Use Attention/Display.

quetiapine, clarithromycin. Either increases the QTc toxicity of the other. Use Attention/Display. Avoid use with drugs that prolong the QT interval and in patients with risk factors for prolonged QT interval. Postmarketing cases show QT prolongation with overdose in patients with comorbidities or drugs known to cause electrolyte imbalance or prolong QT interval.

Clarithromycin will increase the level or effect of quinine by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Use Attention/Display.Clarithromycin and quinine increase the QTc interval. Use Attention/Display.

Clarithromycin will increase the level or effect of quizartinib by affecting hepatic/intestinal CYP3A4 enzyme metabolism. Modify treatment/close monitoring. Reduce quizartinib dose to 26.5 mg per day (if current dose is 53 mg/day) or 17.7 mg per day (if current dose is 26.5 mg/day or 35.4 mg/day). day) when co-administered with strong CYP3A inhibitors. If the current dose is 17.7 mg daily, stop quizartinib while using a strong CYP3A inhibitor. After discontinuing a strong CYP3A inhibitor for 5 half-lives, resume the quizartinib dose taken before starting the strong inhibitor.quizartinib, clarithromycin. Either enhances the effects of the other on the QTc interval Modify treatment/close monitoring. Monitor patients more frequently with an ECG if co-administered with drugs that prolong the QT interval.

Clarithromycin will increase the level or effect of rabeprazole by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Use Attention/Display.

Clarithromycin and ranolazine increase QTc interval Modify treatment/close monitoring.

Rifabutin will decrease the level or effect of clarithromycin by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Use Attention/Display.

Rifampicin will decrease the level or effect of clarithromycin by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Use Attention/Display.

Clarithromycin increases rifaximin levels via the P-glycoprotein efflux transporter (MDR1). Use Attention/Display.

Clarithromycin increases rilpivirine levels by affecting the metabolism of the intestinal/hepatic enzyme CYP3A4. Use Attention/Display. Whenever possible, alternatives such as azithromycin should be considered.Rilpivirine increases the toxicity of clarithromycin during the QTc interval. Use Attention/Detection. Rilpivirine should be used with caution when co-administered with a drug with a known risk of Torsades de Pointes.

Clarithromycin will increase the level or effect of riociguat by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Use Attention/Display.

Clarithromycin will increase the level or effect of ripretinib by affecting hepatic/intestinal CYP3A4 enzyme metabolism. Use Attention/Display. Co-administration with a strong CYP3A inhibitor will increase systemic exposure to ripretinib and its active metabolite (DP-5439), which may increase the risk of adverse effects.

Clarithromycin will increase the level or effect of risperidone via the P-glycoprotein efflux transporter (MDR1). Use Attention/Display.Clarithromycin and risperidone increase QTc interval Modify treatment/close monitoring.

Clarithromycin will increase the level or effect of ritonavir via the P-glycoprotein efflux transporter (MDR1). Use Attention/Display.

Clarithromycin will increase the level or effect of romidepsin via the P-glycoprotein efflux transporter (MDR1). Use Attention/Display.Clarithromycin and romidepsin increase QTc interval Modify treatment/close monitoring.

Clarithromycin increases rosiglitazone levels by affecting hepatic/intestinal metabolism of the CYP3A4 enzyme. Use Attention/Display. May cause hypoglycemia. Closely monitor glucose levels.

Rucaparib will increase the level or effect of clarithromycin by affecting the metabolism of the intestinal/hepatic enzyme CYP3A4. Modify treatment/close monitoring. Adjust the dose of CYP3A4 substrates if clinically indicated.

Clarithromycin will increase the level or effect of sacubitril/valsartan by others (see comment). Use Attention/Display. Results from an in vitro study using human liver tissue indicate that valsartan is a substrate of the hepatic uptake transporter OATP1B1. Co-administration with OATP1B1 inhibitors may increase systemic exposure to valsartan.

Clarithromycin will increase the level or effect of salmeterol by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Use Attention/Display.Clarithromycin and salmeterol increase the QTc interval. Use Attention/Display.

Clarithromycin will increase the level or effect of saquinavir via the P-glycoprotein efflux transporter (MDR1). Use Attention/Display.

Clarithromycin will increase the level or effect of saxagliptin by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Modify treatment/close monitoring. Limit saxagliptin dose to 2.5 mg/day when co-administered with strong CYP3A4 inhibitors.

Selpercatinib increases the QTc toxicity of clarithromycin. Use Attention/Display.

Clarithromycin will increase the level or effect of silodosin via the P-glycoprotein efflux transporter (MDR1). Use Attention/Display.

Clarithromycin will increase the level or effect of sirolimus via the P-glycoprotein efflux transporter (MDR1). Use Attention/Display.

Clarithromycin reduces the effects of sodium picosulfate/magnesium oxide/citric acid anhydrous by altering metabolism. Use Attention/Display. Coadministration with antibiotics reduces efficacy by altering the colonic bacterial flora necessary to convert sodium picosulfate to active drug.

Clarithromycin will increase the level or effect of sofosbuvir/velpatasvir by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Use Attention/Display.

Sorafenib and clarithromycin increase the QTc interval. Use Attention/Display.

St. John's wort will decrease the level or effect of clarithromycin by affecting the metabolism of the intestinal/hepatic enzyme CYP3A4. Use Attention/Display.

stiripentol, clarithromycin. that affect the metabolism of the hepatic/intestinal enzyme CYP3A4. Modify treatment/close monitoring. Stiripentol is an inhibitor and inducer of CYP3A4. Monitor CYP3A4 substrates co-administered with stiripentol for increased or decreased effects. CYP3A4 substrates may require dose adjustment.

Clarithromycin will increase the level or effect of streptomycin via the P-glycoprotein efflux transporter (MDR1). Use Attention/Display.

Clarithromycin will increase the level or effect of sufentanil by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Use Attention/Display.

Clarithromycin will increase the level or effect of sufentanil SL by affecting hepatic/intestinal CYP3A4 enzyme metabolism. Use Attention/Display. Co-administration of sufentanil SL with any CYP3A4 inhibitor may increase the plasma concentration of sufentanil and therefore increase or prolong adverse effects, including potentially fatal respiratory depression.

Clarithromycin and sulfamethoxazole increase QTc interval Modify treatment/close monitoring.

Clarithromycin will increase the level or effect of tacrolimus via the P-glycoprotein efflux transporter (MDR1). Use Attention/Display.

Clarithromycin will increase the level or effect of tacrolimus ointment by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Use Attention/Display.

clarithromycin, tamoxifen. that affect the metabolism of the hepatic/intestinal enzyme CYP3A4. Use Attention/Display. CYP3A4 inhibition reduces the metabolism of tamoxifen to N-desmethyl tamoxifen (active metabolite with similar biological activity).

Clarithromycin will increase the level or effect of tasimelteon by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Use Attention/Display.

Tazemetostat will decrease the level or effect of clarithromycin by affecting the metabolism of the intestinal/hepatic enzyme CYP3A4. Use Attention/Display.

Tecovirimat will decrease the level or effect of clarithromycin by affecting the metabolism of the intestinal/hepatic enzyme CYP3A4. Use Attention/Display. Tecovirimat is a weak inducer of CYP3A4. Monitor the efficacy of sensitive CYP3A4 substrates if co-administered.

Clarithromycin and telavancin increase QTc interval Modify treatment/close monitoring.

Clarithromycin will increase the level or effect of teniposide via the P-glycoprotein efflux transporter (MDR1). Use Attention/Display.

Clarithromycin will increase the level or effect of terbinafine by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Use Attention/Display.

Clarithromycin will increase the level or effect of tezacaftor by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Modify treatment/close monitoring. Adjust tezacaftor dosing regimen if co-administered with a strong CYP3A inhibitor.

Clarithromycin will reduce the level or effect of thiamine by altering the intestinal flora. Applies only to the oral form of both agents. Use Attention/Display.

Clarithromycin increases ticagrelor levels by affecting the metabolism of the intestinal/hepatic enzyme CYP3A4. Use Attention/Display. Ticagrelor is metabolized by CYP3A4/5. Avoid use with strong CYP3A inhibitors.

Clarithromycin will increase the level or effect of tinidazole by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Use Attention/Display.

Clarithromycin increases tisotumab vedotin levels by affecting hepatic/intestinal CYP3A4 enzyme metabolism. Use Attention/Display. The active metabolite of tisotumab vedotin (MMAE) is a substrate of CYP3A4. Co-administration with strong CYP3A4 inhibitors may increase systemic exposure to unconjugated MMAE and increase the risk of adverse effects.

Clarithromycin will increase the level or effect of tobramycin via the P-glycoprotein efflux transporter (MDR1). Use Attention/Display.

Clarithromycin increases tolasamide levels by antagonizing binding to plasma proteins. Use Attention/Display. Risk of hypoglycemia.

Clarithromycin increases tolbutamide levels by antagonizing binding to plasma proteins. Use Attention/Display. Risk of hypoglycemia.

Clarithromycin will increase the level or effect of tolvaptan via the P-glycoprotein efflux transporter (MDR1). Use Attention/Display.

Clarithromycin will increase the level or effect of tramadol by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Use Attention/Display.

Clarithromycin and trimethoprim increase QTc interval Modify treatment/close monitoring.

Clarithromycin will increase the level or effect of trimipramine by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Use Attention/Display.

Triptorelin increases the toxicity of clarithromycin during the QTc interval. Use Attention/Display. Increases the risk of torsades de pointes.

Clarithromycin and tropisetron increase QTc interval Modify treatment/close monitoring.

Clarithromycin will increase the level or effect of ulipristal by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Use Attention/Display.

Clarithromycin will increase the level or effect of inhaled umeclidinium bromide/vilanterol by affecting hepatic/intestinal CYP3A4 enzyme metabolism. Modify treatment/close monitoring. Vilanderol is a CYP3A4 substrate. Co-administration with strong CYP3A4 inhibitors may increase systemic exposure

Clarithromycin will increase the level or effect of upadacitinib by affecting hepatic/intestinal CYP3A4 enzyme metabolism. Use Attention/Display. Caution if upadacitinib is co-administered with strong CYP3A4 inhibitors.

Clarithromycin will increase the level or effect of valbenazine by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Modify treatment/close monitoring. Reduce valbenazine dose to 40 mg once daily when co-administered with a strong CYP3A4 inhibitor.Valbenazine and clarithromycin increase the QTc interval. Use Attention/Display.

Clarithromycin will increase the level or effect of valsartan by others (see comment). Use Attention/Display. Results from an in vitro study using human liver tissue indicate that valsartan is a substrate of the hepatic uptake transporter OATP1B1. Co-administration with OATP1B1 inhibitors may increase systemic exposure to valsartan.

Clarithromycin will increase the level or effect of vardenafil by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Modify treatment/close monitoring. Limit the dose of vardenafil to 2.5 mg/24 hours.

Clarithromycin will increase the level or effect of velpatasvir by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Use Attention/Display.

Clarithromycin and venlafaxine increase QTc interval Modify treatment/close monitoring.

Clarithromycin will increase the level or effect of verapamil by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Use Attention/Display. Increased activity of calcium channel blockers can cause hypotension, edema, decreased heart rate, and acute kidney injury due to decreased renal blood flow.

Clarithromycin will increase the level or effect of inhaled vilanterol furoate/fluticasone by affecting hepatic/intestinal CYP3A4 enzyme metabolism. Modify treatment/close monitoring. Fluticasone furoate and vilanterol are CYP3A4 substrates. Co-administration with strong CYP3A4 inhibitors may increase systemic exposure

Clarithromycin will increase the level or effect of vinblastine by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Use Attention/Display.Clarithromycin will increase the level or effect of vinblastine via the P-glycoprotein efflux transporter (MDR1). Use Attention/Display.

Clarithromycin will increase the level or effect of vincristine by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Use Attention/Display.Clarithromycin will increase the level or effect of vincristine via the P-glycoprotein efflux transporter (MDR1). Use Attention/Display.

Clarithromycin will increase the level or effect of liposomal vincristine by affecting hepatic/intestinal CYP3A4 enzyme metabolism. Use Attention/Display.Clarithromycin will increase the level or effect of liposomal vincristine via the P-glycoprotein efflux transporter (MDR1). Use Attention/Display.

Clarithromycin will increase the level or effect of vinorelbine by affecting hepatic/intestinal CYP3A4 enzyme metabolism. Use Attention/Display.

voclosporin, clarithromycin. Either one increases the effects of the other on the QTc interval. Use Attention/Display.

Clarithromycin and voriconazole increase QTc interval Modify treatment/close monitoring.

Clarithromycin will increase the level or effect of warfarin by Others (see comment). Use Attention/Display. The less potent R-enantiomer of warfarin is partially metabolized by CYP3A4 (as well as CYP1A2 and CYP2C19). Monitor INR more frequently if co-administered with inhibitors of these isoenzymes and adjust warfarin dose if necessary.

Clarithromycin will increase the level or effect of zanubrutinib by affecting hepatic/intestinal CYP3A4 enzyme metabolism. Modify treatment/close monitoring. Reduce zanubrutinib (a CYP3A4 substrate) to 80 mg orally twice daily when co-administered with a moderate CYP3A4 inhibitor. Discontinue dose as recommended to check for side effects. After stopping the CYP3A4 inhibitor, repeat the previous dose of zanubrutinib.

Clarithromycin increases the toxicity of zidovudine through an unknown mechanism. Use Attention/Display. Increased risk of myelosuppression.clarithromycin, zidovudine. Mechanism: unknown. Use Attention/Display. Clarithromycin can increase or decrease zidovudine levels. The literature describes conflicting reports. Separate administration by at least 2 to 4 hours. .

Clarithromycin will increase the level or effect of ziprasidone by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Use Attention/Display.

Clarithromycin will increase the level or effect of zonisamide by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Use Attention/Display.

Acetazolamide will increase the level or effect of clarithromycin by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Minor/unknown significance.

Clarithromycin will increase the level or effect of aliskiren by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Minor/unknown significance.Clarithromycin will increase the level or effect of aliskiren via the P-glycoprotein efflux transporter (MDR1). Minor/unknown significance.

Clarithromycin will increase the level or effect of alvimopan via the P-glycoprotein efflux transporter (MDR1). Minor/unknown significance.

Clarithromycin will increase the level or effect of ambrisentan by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Minor/unknown significance.Clarithromycin will increase the level or effect of ambrisentan via the P-glycoprotein efflux transporter (MDR1). Minor/unknown significance.

Amobarbital will decrease the level or effect of clarithromycin by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Minor/unknown significance.Amobarbital reduces clarithromycin levels by increasing clearance. Minor/unknown significance.

Clarithromycin reduces the effects of amoxicillin through pharmacodynamic antagonism. Minor/unknown significance.

Clarithromycin reduces the effects of ampicillin through pharmacodynamic antagonism. Minor/unknown significance.

Anastrozole will increase the level or effect of clarithromycin by affecting the metabolism of the intestinal/hepatic enzyme CYP3A4. Minor/unknown significance.

Clarithromycin will increase the level or effect of apixaban by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Minor/unknown significance. Although clarithromycin is a combined inhibitor of P-gp and CYP3A4, the manufacturer stated that the pharmacokinetic data suggest that no dose adjustment is necessary with co-administration.

Aprepitant will increase the level or effect of clarithromycin by affecting the metabolism of the intestinal/hepatic enzyme CYP3A4. Minor/unknown significance.

Armodafinil will decrease the level or effect of clarithromycin by affecting the metabolism of the intestinal/hepatic enzyme CYP3A4. Minor/unknown significance.Clarithromycin will increase the level or effect of Armodafinil via the P-glycoprotein efflux transporter (MDR1). Minor/unknown significance.

Artemether/lumefantrine will decrease the level or effect of clarithromycin by affecting hepatic/intestinal CYP3A4 enzyme metabolism. Minor/unknown significance.

Atazanavir will increase the level or effect of clarithromycin by affecting the metabolism of the intestinal/hepatic enzyme CYP3A4. Minor/unknown significance.

Bosentan will decrease the level or effect of clarithromycin by affecting the metabolism of the intestinal/hepatic enzyme CYP3A4. Minor/unknown significance.

Budesonide will decrease the level or effect of clarithromycin by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Minor/unknown significance.

Butabarbital will decrease the level or effect of clarithromycin by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Minor/unknown significance.Butabarbital reduces clarithromycin levels by increasing clearance. Minor/unknown significance.

Butalbital will decrease the level or effect of clarithromycin by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Minor/unknown significance.Butalbital reduces clarithromycin levels by increasing clearance. Minor/unknown significance.

Clarithromycin increases chlorpropamide levels by an unknown mechanism. Minor/unknown significance. Risk of hepatotoxicity.

Conivaptan will increase the level or effect of clarithromycin by affecting the metabolism of the intestinal/hepatic enzyme CYP3A4. Minor/unknown significance.

Cortisone will decrease the level or effect of clarithromycin by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Minor/unknown significance.

Cyclophosphamide will increase the level or effect of clarithromycin by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Minor/unknown significance.

Cyclosporine will increase the level or effect of clarithromycin by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Minor/unknown significance.

Darifenacin will increase the level or effect of clarithromycin by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Minor/unknown significance.

Darunavir will increase the level or effect of clarithromycin by affecting the metabolism of the intestinal/hepatic enzyme CYP3A4. Minor/unknown significance.

Dasatinib will increase the level or effect of clarithromycin by affecting the metabolism of the intestinal/hepatic enzyme CYP3A4. Minor/unknown significance.

Dexamethasone will decrease the level or effect of clarithromycin by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Minor/unknown significance.

Herbal DHEA will increase the level or effect of clarithromycin by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Minor/unknown significance.

Clarithromycin reduces the effects of dicloxacillin through pharmacodynamic antagonism. Minor/unknown significance.

Dronedarone will increase the level or effect of clarithromycin by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Minor/unknown significance.

Efavirenz will decrease the level or effect of clarithromycin by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Minor/unknown significance.

Eslicarbazepine acetate will decrease the level or effect of clarithromycin by affecting hepatic/intestinal CYP3A4 enzyme metabolism. Minor/unknown significance.

Ethinyl estradiol will increase the level or effect of clarithromycin by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Minor/unknown significance.

Etravirine will decrease the level or effect of clarithromycin by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Minor/unknown significance.

Clarithromycin will increase the level or effect of fexofenadine via the P-glycoprotein efflux transporter (MDR1). Minor/unknown significance.

Fluconazole will increase the level or effect of clarithromycin by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Minor/unknown significance.

Fludrocortisone will decrease the level or effect of clarithromycin by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Minor/unknown significance.

Fosabrenavir will increase the level or effect of clarithromycin by affecting the metabolism of the intestinal/hepatic enzyme CYP3A4. Minor/unknown significance.

Fosaprepitant will increase the level or effect of clarithromycin by affecting the metabolism of the intestinal/hepatic enzyme CYP3A4. Minor/unknown significance.

Fosphenytoin will decrease the level or effect of clarithromycin by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Minor/unknown significance.

clarithromycin, ganaxolone. that affect the metabolism of the hepatic/intestinal enzyme CYP3A4. Minor/unknown significance. Changes in ganaxolone exposure when co-administered with strong, moderate, or weak CYP3A4 inhibitors are not expected to be clinically significant.

Grapefruit will increase the level or effect of clarithromycin by affecting the metabolism of the intestinal/hepatic enzyme CYP3A4. Minor/unknown significance.

Griseofulvin will decrease the level or effect of clarithromycin by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Minor/unknown significance.

Hydrocortisone will decrease the level or effect of clarithromycin by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Minor/unknown significance.

Indinavir will increase the level or effect of clarithromycin by affecting the metabolism of the intestinal/hepatic enzyme CYP3A4. Minor/unknown significance.

clarithromycin, ixazomib. that affect the metabolism of the hepatic/intestinal enzyme CYP3A4. Minor/unknown significance. In clinical trials, co-administration of ixazomib with strong CYP3A inhibitors did not produce a clinically relevant change in ixazomib systemic exposure.

Lapatinib will increase the level or effect of clarithromycin by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Minor/unknown significance.

Clarithromycin will increase the level or effect of loratadine via the P-glycoprotein efflux transporter (MDR1). Minor/unknown significance.

Lumefantrine will decrease the level or effect of clarithromycin by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Minor/unknown significance.

Marijuana will increase the level or effect of clarithromycin by affecting the metabolism of the CYP3A4 liver/gut enzyme. Minor/unknown significance.

Methylprednisolone will decrease the level or effect of clarithromycin by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Minor/unknown significance.Clarithromycin increases methylprednisolone levels by decreasing metabolism. Minor/unknown significance.

Metronidazole will increase the level or effect of clarithromycin by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Minor/unknown significance.

Vaginal miconazole will increase the level or effect of clarithromycin by affecting hepatic/intestinal CYP3A4 enzyme metabolism. Minor/unknown significance.

Clarithromycin reduces the effects of nafcillin through pharmacodynamic antagonism. Minor/unknown significance. Bacteriostatic antibiotics can interfere with the bactericidal activity of penicillins.

Nelfinavir will increase the level or effect of clarithromycin by affecting the metabolism of the intestinal/hepatic enzyme CYP3A4. Minor/unknown significance.

Nevirapine will decrease the level or effect of clarithromycin by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Minor/unknown significance.

Nifedipine will increase the level or effect of clarithromycin by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Minor/unknown significance.

Nilotinib will increase the level or effect of clarithromycin by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Minor/unknown significance.

Clarithromycin reduces the effects of oxacillin through pharmacodynamic antagonism. Minor/unknown significance. Bacteriostatic agents can inhibit the effects of bactericidal agents.

Oxcarbazepine will decrease the level or effect of clarithromycin by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Minor/unknown significance.

Clarithromycin reduces the effects of aqueous penicillin G through pharmacodynamic antagonism. Minor/unknown significance.

Clarithromycin reduces the effects of penicillin VK through pharmacodynamic antagonism. Minor/unknown significance.

Pentobarbital will decrease the level or effect of clarithromycin by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Minor/unknown significance.Pentobarbital decreases clarithromycin levels by increasing clearance. Minor/unknown significance.

Phenobarbital will decrease the level or effect of clarithromycin by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Minor/unknown significance.Phenobarbital reduces clarithromycin levels by increasing clearance. Minor/unknown significance.

Phenytoin will decrease the level or effect of clarithromycin by affecting hepatic/intestinal CYP3A4 enzyme metabolism. Minor/unknown significance.

Clarithromycin reduces the effects of pivmecillinam through pharmacodynamic antagonism. Minor/unknown significance.

Posaconazole will increase the level or effect of clarithromycin by affecting the metabolism of the intestinal/hepatic enzyme CYP3A4. Minor/unknown significance.

Prednisone will decrease the level or effect of clarithromycin by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Minor/unknown significance.

Primidone will decrease the level or effect of clarithromycin by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Minor/unknown significance.Primidone reduces clarithromycin levels by increasing clearance. Minor/unknown significance.

Quinupristin/dalfopristin will increase the level or effect of clarithromycin by affecting the hepatic/intestinal metabolism of the CYP3A4 enzyme. Minor/unknown significance.

Clarithromycin will increase the level or effect of ramelteon by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Minor/unknown significance.

Rifapentine will decrease the level or effect of clarithromycin by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Minor/unknown significance.

Ritonavir will increase the level or effect of clarithromycin by affecting the metabolism of the intestinal/hepatic enzyme CYP3A4. Minor/unknown significance.

Rufinamide will decrease the level or effect of clarithromycin by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Minor/unknown significance.

Secobarbital will decrease the level or effect of clarithromycin by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Minor/unknown significance.Secobarbital reduces clarithromycin levels by increasing clearance. Minor/unknown significance.

Clarithromycin reduces the effects of temocillin through pharmacodynamic antagonism. Minor/unknown significance.

Clarithromycin increases theophylline levels by decreasing metabolism. Minor/unknown significance.

Clarithromycin reduces the effects of ticarcillin through pharmacodynamic antagonism. Minor/unknown significance.

Topiramate will decrease the level or effect of clarithromycin by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Minor/unknown significance.

Clarithromycin increases valproic acid levels by slowing metabolism. Minor/unknown significance.

Verapamil will increase the level or effect of clarithromycin by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Minor/unknown significance.

Voriconazole will increase the level or effect of clarithromycin by affecting the metabolism of the intestinal/hepatic enzyme CYP3A4. Minor/unknown significance.

Zafirlukast will increase the level or effect of clarithromycin by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Minor/unknown significance.

Clarithromycin will increase the level or effect of zaleplon by affecting the metabolism of the intestinal/hepatic enzyme CYP3A4. Minor/unknown significance.

Clarithromycin will increase the level or effect of zolpidem by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Minor/unknown significance.